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COPD  - Chronic Obstructive Pulmonary Disease 
PPOP  -  Push- pull Osmotic Pump 
KCl  -  Potassium Chloride 
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 In the recent years, considerable attention has been made in the 
development of novel drug delivery systems (NDDS) 1. Among the novel drug 
delivery systems, per oral controlled drug delivery system plays a vital role in the 
major market share due to their ease of administration and their capability to 
improve patient compliance2. The per oral controlled drug delivery system provides 
significant benefits over immediate release formulations, moreover  these products 
show reduced side effects due to their simplified dosing schedule. Orally controlled 
drug delivery system provides greater effectiveness in the treatments of chronic 
diseased conditions like Chronic obstructive pulmonary diseases(COPD), Cardiac 
diseases, Diabetes, etc., There are different types of dosage designs are available to 
modulate or control the drug release from a system. Most of the oral controlled 
dosage forms include matrix, reservoir or osmotic systems. The matrix systems are 
made up of either swellable or non-swellable polymers are blended with the active 
ingredient forms a viscous gel when water has been absorbed by the system and 
slowly erodes exposing the drug into the surrounding medium. While in the 
reservoir systems the drug is encapsulated within a water insoluble polymer which 
allows the drug to diffuse through the membrane into the release medium. The 
matrix or reservoir type can contain the immediate release dosage form of the drug. 
However, the release of drug from these systems may be affected by the factors like 
pH, presence or absence of food and other physiological factors from both 
conventional and controlled release systems3. To eradicate these issues a novel 
osmotic systems are developed. 
 Oral osmotically controlled system mainly works on the principle of 
osmosis. This system utilizes osmotic pressure for the release of drug. Drug release 
from these systems is independent of pH and other physiological parameter to a 
large extent and it is possible to modulate the release characteristic by optimizing the 
properties of drug and system4. Various types of oral osmotic pumps are available to 
control the drug delivery over a prolonged period.  
1.1 Principle of Osmosis 
 Osmosis refers to the movement of solvent from region of lower 
concentration to a region of higher concentration through semi permeable 
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membrane. The first osmotic effect was reported by Abbe Nollet in 1748. But the 
quantitative measurement of osmotic pressure was shown by Peffer in 1877, by 
performing an experiment in which he attempted to separate sugar solution from 
pure water through semi-permeable membrane. He also proved that the osmotic 
pressure of the sugar solution is directly proportional to the concentration of solution 
and absolute temperature.  
 Later, Vant Hoff in 1886 identified an existing proportionality between 
osmotic pressure, concentration of solution and temperature. Based on this he 
proved proportionality between these results and ideal gas law equation (1) by the 
following expression 
 𝜋 =  ∅𝑐𝑅𝑇                                                                          (1) 
where Ø is the osmotic coefficient of the solution (equal to 1 for dilute solutions) 
and where c is the molar concentration of sugar (or other solute) in the solution, R is 
the gas constant, and T the absolute temperature. Osmotic pressures for concentrated 
solution of the solutes are extremely high ranging up to 500 atm. The osmotic 
pressure can cause high water permeability across the membrane. The water 
permeability through the membrane by osmosis can be given by the equation (2) 
𝑑𝑉
𝑑𝑡
= 𝐴𝜃∆𝜋
𝑙
                 (2) 
wheredV/dt is the water flow across the membrane of the area𝐴, thickness𝑙, and 
osmotic permeability 𝜃 in cm3.cm/cm2.h.atm and ∆𝜋  is the osmotic pressure 
difference between the two solutions on either side of the membrane. Cellulosic 
polymers, particularly cellulose acetate are commonly used. Typical values for the 
osmotic water permeability of cellulosic membranes range from 1 X10-5 to 1 X10-7 
cm3.cm/cm2.h.atm5.  
1.2 Classification of osmotic controlled drug delivery system 
 The osmotic pump can be classified into two categories viz., oral osmotic 
pump and implantable osmotic devices. 
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1.2.1  Implantable Devices 
A. The Rose and Nelson Pump 
 Rose and Nelson the two Australian physiologists were the first to develop 
osmotic systems based on the principle of Osmosis6. This system comprises of three 
chambers: a drug chamber, a salt chamber and a water chamber as shown in the 
Fig.1. The drug and water chamber was separated by a rigid semi permeable 
membrane. The difference in osmotic pressure across the membrane moves water 
chamber into salt chamber resulting increase in the volume of salt chamber which in 
turn pumps the drug out of the device7. 
 The pumping rate of Rose-Nelson pump is given by equation (3) 
 
dm dv xC
dt dt
=                                         (3) 
wheredMt/dt is the drug release rate, dV/dt is the volume flow of water into the salt 
chamber, and c is the concentration of drug in the drug chamber.  
 
Fig.1 Three chambered Rose-Nelson Osmotic pump 
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B. Higuchi-Leeper Pump 
 A number of simplifications of Rose-Nelson pump have been made by 
Higuchi and Leeper. Higuchi and Leeper simplified Rose-Nelson pump by removing 
the water chamber from Rose-Nelson device. The Higuchi and Leeper device is 
activated after the penetration of water inside the device from the surrounding 
environment. Higuchi Leeper pump is widely used for vertinary use. This type of 
pump is either implanted or swallowed by the animal for delivery antibiotic or 
growth hormones. Higuchi Leeper pump consist of rigid semi permeable membrane 
and an elastic diaphragm made up of microcrystalline paraffin wax (Low melting 
wax) to separate the drug and osmotic chamber is represented in the Fig.2. The 
pulsatile release was achieved by the production of a critical pressure at which the 
delivery orifice opens and releases the drug8.   
 
Fig.2 Higuchi-Leeper pump 
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C. Higuchi Theeuwes Pump 
 Higuchi and Theeuwes developed variant type of Rose and Nelson pump which is 
simpler than the Higuchi Leeper pump. The design of Higuchi Theeuwes pump is 
depicted in Fig. 3.  This device was made of rigid housing which is made up of semi 
permeable membrane which is strong enough to withstand the pressure created by 
the permeation of water. The drug is loaded prior to the application of device. The 
release of drug from device can be controlled by the salt chamber, permeation 
capability of the outer membrane and orifice. Mixture of citric acid and sodium 
bicarbonate in salt chamber in the presence of water generate carbon di-oxide gas, 
which exert a pressure on the elastic diaphragm, eventually delivers the drug through 
orifice9.  
 
Fig.3 Higuchi Theeuwes Pump 
1.2.2  Oral Osmotic Pumps: 10, 11 
 The oral osmotic pump can be classified in to following types: 
1. Single Chamber Osmotic Pump 
• Elementary osmotic pump 
2. Multi Chamber Osmotic Pump 
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• Push pull osmotic pump. 
• Osmotic pump with non-expanding second chamber. 
3. Specific Types 
• Controlled porosity osmotic pump. 
• Monolithic osmotic systems. 
• Bursting osmotic pump. 
• Multi particulate delayed release systems.  
• Liquid oral osmotic system.  
1. Single Chamber Osmotic Pump 
Elementary Osmotic pump (EOP): 
 The elementary osmotic pump (EOP) was introduced by F.Theeuwes 
shown in Fig.4. The EOP consists of an osmotic core, with the drug surrounded by 
the semi permeable with a delivery orifice. EOP was the simplest form of oral 
osmotic pumps which are desired to deliver the drug through an aperture at zero 
order rates.  
 
Fig.4 Theeuwes Elementary osmotic pump. 
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 EOP consists of a drug core with an osmogent surrounded by a semi 
permeable membrane with a delivery orifice. But these elementary osmotic pumps 
are suitable for the moderately soluble drugs. Most of the drugs are differ in their 
solubility properties, this parameter can also influence on the selection design which 
is suitable for the release rate of the drug. 
2. Multi Chamber Osmotic Pump 
Push-pull osmotic pump (PPOP) 
 Push-pull osmotic pump is the modification of simple EOP, through which 
it can deliver both poorly water soluble and freely water soluble drugs at a constant 
rate12. It is a bilayer tablet coated with semi permeable membrane.  The PPOP 
consist of two layers separated usually by an elastic diaphragm. The upper layer 
contains the drug and it is communicated with the outer environment via a small 
delivery orifice. A swellable polymer osmotic agent is present in the lower layer 
comprising of about 20-40 percent of the core tablet weight. The upper drug layer 
comprises of about 60-80 percent of the tablet weight. PPOP can also be used to 
deliver drugs which are extremely soluble in water. There are number of 
modifications are available for altering the release of drug such as delayed push-pull, 
multilayer push-pull system and Push stick system13. Fig. 5 shows the schematic 
representation of the push pull osmotic pump before and after operation. 
 
Fig. 5 Push pull osmotic pump 
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Osmotic pump with non-expanding second chamber 
 The second category of multi-chamber devices comprises of system 
containing a non-expanding second chamber. This can be divided into two types 
based on the nature of the function of second chamber. In one category of these 
devices, the second chamber is used to produce the drug solution leaving the 
devices. This can reduce the GI irritation caused due to the saturated solution of the 
drug that leaves the oral osmotic devices. This type consists of two rigid chamber, 
the first containing the biologically inert osmotic agent, such as sodium chloride, the 
second chamber contains the drug. The solution of osmotic agent formed in the first 
chamber then passes through the connecting hole to the drug chamber where it 
mixes with the drug solution before exiting through the micro porous membrane that 
form a part of wall in the surrounding the chamber. The device could be used to 
deliver relatively insoluble drugs14. 
1.2.3  Specific Types 
• Controlled porosity osmotic pump 
 Controlled porosity osmotic pump is a simple form of osmotic pump which 
consists of drug core surrounded by a semi permeable membrane with water soluble 
components. These water soluble compounds when comes into contact with water  it 
gets dissolved and forms minute pores through which the active drug molecule is 
released for desired period of time. In this type the release rate is depends upon 
water permeability15, osmotic pressure of the core tablet, thickness of the membrane 
and total surface area of coating. The water flow rate into the system can be 
described by equation (4), 
 𝑑𝑣
𝑑𝑡
= 𝐴𝑘
ℎ
(Dp-DR)                      (4) 
where k =  membrane permeability, 
 A =  Area of the membrane, 
 Dp =  Osmotic pressure difference 
 DR  =  Hydrostatic pressure difference 
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• Monolithic Osmotic Pump 
 Monolithic osmotic pump is comprises of simple dispersion of water 
soluble agents in a polymer matrix. When the system comes into contact with the 
aqueous environment, the water imbibition takes place by the active agents and 
causes the polymer matrix to get rupture resulting in liberation of drug into the 
outside environment. Initially the rupture starts in the outer polymer matrix and 
slowly protrudes to the interior polymer matrix in a series. However, this system 
fails if more than 20 to 30% volume of active agent is incorporated into the device, 
as above this level, significant contribution from the simple leaching of the 
substance takes place16. 
• Bursting Osmotic Pump 
 In this type of osmotic pump the drug release is expected to be as same in 
the EOP. The only difference is the delivery orifice size or absence of the delivery 
orifice. When it is placed in an aqueous medium the water imbibed and the 
hydrostatic pressure is built up inside until the wall rupture and the contents are 
released to the environment. The release rate can be controlled by varying the 
thickness of the membrane and the area of the membrane. This system is suitable for 
pulsated release drug delivery mechanism17. 
• Sandwiched Osmotic Tablets 
 It is composed of polymeric push layer sandwiched between two drug 
layers with two delivery orifices18. When placed in the aqueous medium the middle 
layer containing the swelling agents, swells and pushes the drug through the delivery 
orifices. The advantage of this type of system is that the drug is released from the 
two orifices situated in opposite sides of the tablets and thus helps this system to 
deliver drugs of different solubility simultaneously. 
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• Multi Particulate Delayed Release System (MPDRS) 
 MPDRS consist of pellets comprises of drug with or without osmotic agent, 
which are coated with a semi permeable membrane .When this system comes in 
contact with the aqueous environment, water penetrates in the core and forms a 
saturated solution of soluble component. The osmotic pressure difference results in 
rapid expansion of the membrane, leading to the formation of pores. The osmotic 
agent and the drug released through the pores according to zero order kinetics. The 
lag time and dissolution rate were found to be dependent on the coating level and the 
osmotic properties of the dissolution medium19. 
• Liquid Oral Osmotic System (L-OROS) 20, 21 
 To overcome the drug solubility issue Alza developed the L-OROS system 
where the liquid soft gelatin product containing the drug in a dissolved state is 
initially manufactured and then coated with a barrier membrane, then the osmotic 
push layer and then semi permeable membrane containing a drilled orifice. Liquid 
OROS are designed to deliver drugs as liquid formulations and combine the benefits 
of extended release with high bioavailability. 
 They are of two types: - 
• L- OROS Hard cap, 
• L- OROS Soft cap 
 Each of these systems includes a liquid drug layer, an osmotic engine or 
push layer and a semi permeable membrane coating. When the system is in contact 
with the aqueous environment water permeates across the rate controlling membrane 
and activate the osmotic layer. The expansion of the osmotic layer results in the 
development of hydrostatic pressure inside the system, thereby forcing the liquid 
formulation to be delivered from the delivery orifice. Whereas L OROS hardcap or 
softcap systems are designed to provide continuous drug delivery, the L OROS 
delayed liquid bolus drug delivery system is designed to deliver a pulse of liquid 
drug. The delayed liquid bolus delivery system comprises three layers: a placebo 
11 
 
delay layer, a liquid drug layer and an osmotic engine, all surrounded by rate 
controlling semi permeable membrane. The delivery orifice is drilled on the placebo 
layer end of the capsule shaped device. When the osmotic engine is expands, the 
placebo is released first, delaying release of the drug layer. Drug release can be 
delayed from I to 10 hour, depending on the permeability of the rate controlling 
membrane and thickness of the placebo layer. 
1.3  Basic Elements of Oral Osmotic Controlled Drug Delivery Systems22 
 An osmotic pump should contain the following components to attain the 
desired control over the drug release. 
 Drug  
 Osmotic agent 
 Polymer   
 Delivery orifice 
 Semi permeable membrane 
Drug 
 The drug candidate should possess the following characteristics to be 
designed as an oral osmotic drug delivery system. 
 Short biological half-life (2-6 hours) 
 The drug must be highly potent 
 Used to treat chronic diseases like Cardiac diseases, asthma, diabetes, 
etc., 
 Drugs like Nifedipine, Salbutamol, Theophylline, Glipizide etc., are 
suitable candidates for oral osmotic drug delivery system. 
 
 
12 
 
Osmotic Agent 
 Osmogents used for the design of osmotic dispensing device areinorganic 
or organic in nature a water soluble drug can itself serve as an osmogent. 
Inorganic Osmogents 
Magnesium sulphate, Sodium chloride, Sodium sulphate, Potassiumchloride, 
Sodiumbicarbonate. 
Polymer 
 Mostly hydrophilic polymers are preferred in Oral osmotic drug delivery 
system to provide controlled release of the drug. Sodium carboxymethyl cellulose, 
Hydroxypropyl Methylcellulose, HydroxyEthylcellulose, Methyl cellulose, 
PolyEthyleneoxide, Polyvinyl Pyrollidone. 
Delivery Orifice 
 Delivery orifice plays a vital role in controlling the release rate of drug 
from the osmotic system. The size of the orifice does not show any significant 
variation in drug release if it is altered within certain limits.   
Semipermeable Membrane 
 The semi permeable membrane must be stable to both the inner and outer 
environment of the delivery system. The membrane must be rigid enough to 
withstand the pressure produced by the osmotic agent when it is exposed to the 
release media. The membrane should be highly permeable to water and impermeable 
to the drug contents and the dispenser so that the osmogent is not lost by diffusion across 
the membrane. Moreover the membrane should abide with the biological system. 
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1.4  Advantages and Disadvantagesof Oral Osmotic Controlled Drug 
DeliverySystems 23, 24, 25 
 Osmotic drug delivery system for oral and parenteral use offer distinct and 
practical advantage over other means of delivery. The advantages of the osmotic 
controlled drug delivery systems are as follows:  
• It provides a zero order release of drug after an initial lag period. 
• The release of drug can be modulated or delayed if desired. 
• Drug release from this system is independent of pH and other 
physiological factors. 
• Release rate from this system is highly predictable and minimally 
affected by the presence or absence of food, which can be easily 
programmed by altering the release control parameters. 
• In-vitro in-vivo correlation (IVIVC) obtained from this osmotic pump 
is highly reliable. 
• Drugs of different solubility can be fabricated by this technique. 
• Delivery rate of the drug from this system is independent of agitation, 
delivery orifice provided some limitations. 
• An osmotic delivery system is capable of providing not only a 
prolonged zero-order release, but also a delivery rate much higher 
than that achievable by the solution-diffusion mechanism. 
1.4.1 Disadvantages of Oral Osmotic Controlled Drug Delivery Systems 
• Expensive. 
• Termination of therapy is not possible in case of any unexpected 
adverse effects. 
• Rapid development of Tolerance. 
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1.5 Drug release rate controlling factors 26, 27 
 There are three significant parameters which can be altered to modulate the 
release rate of the drug from the oral osmotic controlled drug delivery system. 
 Solubility  
 Osmotic pressure 
 Size of the delivery orifice 
 Membrane thickness 
1.5.1  Solubility 
 The solubility of the Active Pharmaceutical Ingredients (API) should be in 
the desired range such that the release rate can be optimized based on the solubility 
property of the drug. In case of poorly soluble drugs the solubility can be modulated 
within the core tablet by using suitable agents to enhance solubility and to produce 
the effective release pattern of the drugs. 
Solubility Enhancement Methods 
• Use of cyclodextrin derivatives are known to improve the solubility 
of the poorly soluble drugs.  
• Change in the nature of the salt form can be able to change the 
solubility of the drug. 
• Solubility modifier excipients are used in the form mini-tablet coated 
with rate controlling membrane. 
• Different types of excipients are available for modulation of pH 
dependent solubility of APIs.  
1.5.2  Osmotic Pressure 
 The next release controlling factor is the osmotic pressure gradient between 
inside the compartment and the external environment.  The osmotic pressure 
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difference across the membrane controls the release rate of the drug from the 
system. The simplest way to achieve a constant osmotic pressure within the 
compartment is to maintain an osmotic agent with in the compartment. Table 1 
shows the osmotic pressure produced by the solutes used in the controlled release 
formulations. 
1.5.3  Size of the Delivery Orifice 
 To attain a desired zero order release the size of the delivery orifice should 
be minimum than the maximum size of the delivery orifice. Usually the delivery 
orifice size ranges from 300μm to 1mm.                                                                    
Table 1List of osmotic agents commonly used in osmotic systems28 
S. No. Compounds of mixture Osmotic pressure (atm) 
1. Lactose-Fructose 500 
2. Dextrose-Fructose 450 
3. Sucrose-Fructose 430 
4. Mannitol-Fructose 415 
5. Sodium chloride 356 
6. Fructose 335 
7. Lactose-Sucrose 250 
8. Potassium chloride 245 
9. Lactose-Dextrose 225 
11. Dextrose-Sucrose 190 
13. Sucrose 150 
15. Dextrose 82 
17. Mannitol 38 
18. Lactose 23 
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Table 2  Patents of drug formulation in the form of elementary osmotic pump28 
Year U.S. Patent No. Drug 
1986 4612008 Diclofenac sodium 
1988 4765989 Nifedipine and α blocker 
1988 4783337 Calcium antagonist, ACE inhibitor 
1989 4812263 Isadipine 
1989 4837111 Doxazocin 
1989 4859470 Diltiazem 
1990 4904474 Beclomethasone 
1990 4948593 Contraceptive Steroid 
1991 5024843 Glipizide 
1991 5028434 Nivadipine 
1992 5160744 Verapamil 
1992 5091190 Glipizide 
1993 5185158 Tandopirone 
1993 5192550 Antiparkinsons drug 
1993 5248310 Beclomethasone (oral) 
1996 5545413 Glipizide 
1997 5591454 Glipizide 
2003 20030224051 Oxycodone 
2004 20040091529 Topiramine 
2005 20050232995 Resperidone and Paliperidone 
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Table 3Patents of drug formulations in the form of multi chamber osmotic 
pump28 
Year U.S. Patent No. Drug 
1981 4265874 Indomethacin 
1981 4305927 Acetazolamide 
1984 4439195 Theophylline 
1984 4484921 Theophylline 
1986 4610686 Haloperidol 
1987 4662880 Pseudoephedrine &Bromopheniramine 
1988 4732195 Haloperidol 
1988 4751071 Salbutamol 
1989 48573300 Chlopheniramine 
1991 4986987 Imenhydrinate 
1992 147654 Buccal nicotine 
1993 200194 
Mucosal delivery of anti-plague agent and 
nicotine 
1998 5776493 Mucosal delivery of Nystatin 
1999 5869096 Mucosal osmotic delivery of Levodopa 
2003 20030143272 Nifedipine formulation 
2005 20050053653 Low water soluble drugs 
 
 
 
 
 
 
18 
 
List of Marketed Products Available 
Acutrim 
• ActivePharmaceutical Ingredient: Phenylpropanolamine Hcl 
• Design : Elementaryosmotic pump 
• Dose : 75 mg 
Alpress LP 
• Active Pharmaceutical Ingredient : Prazosin 
• Design : Push-Pullosmotic pump 
• Dose : 2.5,5 mg 
CarduraXL 
• Active Pharmaceutical Ingredient : Doxazosin 
• Design : Push-Pullosmotic pump 
• Dose : 4,8 mg 
CoveraHS 
• Active Pharmaceutical Ingredient :Verapamil 
• Design :Push -Pullosmoticpump with time delay 
• Dose : 180, 240 mg 
DitropanXL 
• Active Pharmaceutical Ingredient :Oxybutinin chloride 
• Design :Push–Pullosmoticpump 
• Dose : 5, 10 mg 
19 
 
 
DynacircCR 
• Active Pharmaceutical Ingredient :Isradipine 
• Design :Push–Pullosmoticpump 
• Dose : 5, 10 mg 
Efidac 24 
• Active Pharmaceutical Ingredient :Pseudoephiderine 
• Design :ElementaryPump 
• Dose : 60 mg IR, 180 mg CR 
Efidac 24 
• ActivePharmaceuticalIngredient:Chlorpheniraminemeleate 
• Design :ElementaryPump 
• Dose : 4 mg IR, 12mgCR 
GlucotrolXL  
• Active Pharmaceutical Ingredient :Glipizide 
• Design :Push-Pullosmotic pump 
• Dose : 5, 10 mg 
Sudafed 24® 
• Active Pharmaceutical Ingredient :Pseudoephedrine Hcl 
• Design :Elementary osmotic pump 
Volmex® 
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• Active Pharmaceutical Ingredient :Albuterol 
• Design :Elementary osmotic pump 
Minipress XL® 
• Active Pharmaceutical Ingredient :Prazocine 
• Design :Elementary osmotic pump 
Procadia XL® 
• Active Pharmaceutical Ingredient :Nifedipine 
• Design : Push-Pullosmotic pump 
Invega® 
• Active Pharmaceutical Ingredient :Paliperidone 
• Design : Push-Pull osmotic pump 
Viadur® 
• Active Pharmaceutical Ingredient :Leuprolide acetate 
• Design :Implantable osmoticsystem 
ChronogesicTM 
• Active Pharmaceutical Ingredient : Sufentanil 
• Design :Implantable osmoticsystem 
1.6  Hypertension and Management29 
 High blood pressure (HBP) or hypertension means high pressure (tension) 
in the arteries. Arteries are vessels that carry blood from the pumping heart to all the 
tissues and organs of the body. High blood pressure does not mean excessive 
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emotional tension, although emotional tension and stress can temporarily increase 
blood pressure. Normal blood pressure is below 120/80; blood pressure between 
120/80 and 139/89 is called "pre-hypertension", and a blood pressure of 140/90 or 
above is considered high. The systolic blood pressure corresponds to the pressure in 
the arteries as the heart contracts and pumps blood forward into the arteries. The 
bottom number, the diastolic pressure, represents the pressure in the arteries as the 
heart relaxes after the contraction. The diastolic pressure reflects the lowest pressure 
to which the arteries are exposed.The pressure exerted by blood within the artery is 
shown inFig. 6. 
 
Fig. 6Blood pressure within the artery 
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 An elevation of the systolic or diastolic blood pressure increases the risk of 
developing cardiac disease, renal disease, atherosclerosis or arteriosclerosis, eye 
damage, and stroke. These complications of hypertension are often referred to as 
end-organ damage because damage to these organs is the end result of chronic high 
blood pressure. For that reason, the diagnosis of high blood pressure is important so 
efforts can be made to normalize blood pressure and prevent complications. It was 
previously thought that rises in diastolic blood pressure were a more important risk 
factor than systolic elevations, but it is now known that in people 50 years or older 
systolic hypertension represents a greater risk. Hypertension is clearly a major 
public health problem.  
1.7.1  Management of Hypertension: 
 Diuretics 
o Thiazides: Hydrochlorothiazide, Chlorthalidone, Indapamide 
o High ceiling: Furosemide, etc. 
o K' Sparing: Spironolactone,Amiloride 
 ACE inhibitors 
o Captopril, Enalapril, Lisinopril, Perindopril, Ramipril, Fosinopril, etc. 
 Angiotensin (AT, receptor) blockers 
o Losartan, Candesartan, Irbesartan, Valsartan, Telmisartan 
 Calcium channel blockers 
o Verapamil, Diltiazem, Nifedipine, Felodipine, Amlodipine, 
Nitrendipine, Lacidipine, etc. 
  Adrenergic blockers 
o Propranolol, Metoprolol, Atenolol, etc. 
 B  Adrenergic blockers 
o Labetalol, Carvedilol 
 α Adrenergic blockers 
o Prazosin, Terazosin, Doxazosin, Phentolamine, Phenoxybenzamine 
 Centralsympatholytics 
o Clonidine, Methyldopa 
 Vasodilators 
o Arteriolar: Hydralazine,Minoxidil,Diazoxide 
o Arteriolar + uenlus: Sodium nitroprusside 
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2. Review of Literature 
 Zhi-hong Zhang et al.,30 have designed an expert system for the selection of 
excipients and the method for the preparation of push pull osmotic pump 
containing poorly water soluble drugs. For this work they had chosen 
Famotidine as a model drug. Neural networks, VB.NET associating with 
SQL server were used to design the expert system. Till now this is the only 
expert system available for designing of controlled drug delivery systems. 
 Chanmanlal Shishoo et al.,31 the push-pull osmotic pump have been 
developed for zero order delivery of Lithium Carbonate for a period of 24 h. 
The effect of various formulation variables on bilayer core tablet and its semi 
permeable coating along with orifice diameter have been investigated and 
optimized for desired drug release profile. Drug release was found to be 
inversely proportional to the membrane thickness but directly related to the 
amount of pore formers in the semipermeable membrane. Images from a 
scanning electron microscope confirmed the presence of pores in the 
semipermeable membrane which facilitated the required water penetration. 
No distortion or change in orifice shape was noticed prior to and after the 
dissolution study. Drug release from the developed formulation was found to 
be independent of pH, agitation intensity and agitation mode but depended 
on osmotic pressure of dissolution media. 
 Rajagopal Kumaravelrajan et al.,32 Controlled porosity osmotic pump 
tablet(CPOP) system was designed to deliver Nifedipine (NP) and 
Metoprolol (MP) in a controlled manner up to 12 h. Formulation variables 
like type and level of pore former and percent weight gain of membrane was 
found to affect the drug release from the developed formulations. Drug 
release was inversely proportional to the membrane weight but directly 
related to the level of pore former. Burst strength of the exhausted shell was 
inversely proportional to the level of pore former, but directly affected by the 
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membrane weight. Results of scanning electron microscopy (SEM) studies 
showed the formation of pores in the membrane from where the drug release 
occurred. Dissolution models were applied to drug release data in order to 
establish the mechanism of drug release kinetics. In vitro release kinetics was 
subjected to superposition method to predict in vivo performance of the 
developed formulation. The developed osmotic system is effective in the 
multi-drug therapy of hypertension by delivering both drugs in a controlled 
manner. 
 K Latha et al.,33developed an optimized press-coated tablet of Losartan 
Potassium using a mixture of hydrophilic polymer, Hydroxy propyl 
methylcellulose (HPMC) and microcrystalline cellulose (MCC) in order to 
achieve a predetermined lag time for chronotherapy. The press-coated tablets 
(PCT) containing Losartan Potassium in the inner core were prepared by 
compression-coating with HPMC 100KM alone and admixed with MCC as 
the outer layer in different ratios. The optimised formulation was further 
characterized with Fourier-transform infrared spectroscopy (FTIR) and 
powder X-ray diffractometry (PXRD) to investigate any drug/excipient 
modifications/interactions. The release profile of the press-coated tablet 
exhibited a distinct lag time before burst release of Losartan Potassium. Lag 
time was dependent on the ratio of HPMC/MCC in the outer shell. The lag 
time was from 0.5 to 18.5 h and could be modulated as it decreased as the 
amount of MCC in the outer layer increased. There was no modification or 
chemical interaction between the drug and the excipient. Formulation LPP2, 
with HPMC/MCC of (30:70) in the outer shell and showing a predetermined 
lag time of 6 h prior to burst release of the drug from the press-coated tablet 
was taken as the optimized formulation. 
 Stuti Gupta et al.,34  Studied Conventional drug delivery systems of  have 
little control over their drug release and almost no control over the effective 
concentration at the target site. This leads to constantly changing, 
unpredictable plasma concentrations. Drugs can be delivered in a controlled 
pattern over a long period of time by the process of osmosis. Osmotic 
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devices are the most promising strategy based systems for controlled drug 
delivery. They are the most reliable controlled drug delivery systems and 
could be employed as oral drug delivery systems. The present review is 
concerned with the study of drug release systems which are tablets coated 
with walls of controlled porosity. When these systems are exposed to water, 
low levels of water soluble additive is leached from polymeric material i.e. 
semi permeable membrane and drug releases in a controlled manner over an 
extended period of time. Drug delivery from this system is not influenced by 
the different physiological factors within the gut lumen and the release 
characteristics can be predicted easily from the known properties of the drug 
and the dosage form. In this paper, various types of osmotically controlled 
drug delivery systems and the basic components of controlled porosity 
osmotic pump tablets have been discussed briefly. 
 Tanmoy Ghosh et al.,35 Formulated Immediate release conventional dosage 
form lack in the efficiency of controlling the proper plasma drug 
concentration. This results in the development of various controlled drug 
delivery system. Among which the Pulsatile drug delivery systems (PDDS)/ 
osmotic drug delivery system (ODDS) are gaining importance as these 
systems deliver the drug at specific time as per the path physiological need of 
the disease, resulting in improved patient therapeutic efficacy and 
compliance. They work on the principle of osmotic pressure for controlling 
the delivery of the drug. The release of the drug is independent of 
physiological factors of the Gastro Intestinal Tract GIT to a large extent. This 
review highlights’ the theoretical concept of drug delivery, history, types of 
oral osmotic drug delivery systems, factors affecting the drug delivery 
system, advantages and disadvantages of this delivery systems ,theoretical 
aspects, applications, marketed status and last but not the least the recent 
development. 
 Kh.Hussan Reza et al.,36 developed a monolithic osmotic tablet of 
Aceclofenac coated with cellulose acetate (CA) and membrane drilled with 
two orifices on both side surfaces, has been described. The influences of 
26 
 
tablet formulation variables including amount of polymer Explotab (Expt), 
amount of sodium chloride (NaCl), have been investigated. Orifice size and 
membrane variables including nature and amount of plasticizers as well as 
thickness on drug release have also been studied. The in vitro release profiles 
of the optimal system have been evaluated in various release media and 
different agitation rates, and compared with commercialized conventional 
tablet. It was found that the amount of Explotab and Nacl showed profoundly 
positive effects on drug release. It could be found that the optimal orifice size 
was 800 μm. It has also been observed that hydrophilic plasticizer 
polyethylene glycol (PEG) improved drug release, when they were 
incorporated in CA membrane. The monolithic osmotic tablet system was 
found to be able to deliver Aceclofenac at the rate of approximate zero-order 
up to 24 h, independent of both environmental media and agitation rate. The 
monolithic osmotic tablet system may be used in drug controlled delivery 
field, especially suitable for water-insoluble drugs. 
 R.Vijaya Muthumanikandar et al.,37 The buccoadhesive controlled release 
tablets of Losartan Potassium were prepared by Wet granulation method 
using the Carbopol 934P, HydroxyPropylcellulose, sodium alginate and 
sodium CMC as bioadhesive polymer. The tablets were evaluated for the 
Pre-compression Parameters and post compression parameter like 
bioadhesive strength, In vitro retention time, and In vitro drug release study. 
The thickness and weight of the tablets, respectively, ranges from 2.3 ± 0.01 
and 2.5 ± 0.02 and the weight of tablets ranges from 148-152mg.The 
Formulation containing sodium CMC and Sodium alginate shows acceptable 
bioadhesive strength but erode respectively, with in 6 to 8 hours. The tablet 
formulation containing carbopol and HPC shows higher bioadhesive 
strength, sustained release of drug and sufficient In vitro retention time. The 
optimized formulation obeys the first order release kinetics. 
 Beom-Jin Lee et al.,38 were prepared solid dispersion granules of a poorly 
water soluble drug. For this study Losartan potassium was chosen as the 
model drug because of its pH dependent solubility and short elimination 
27 
 
half- life. A free flowing Solid dispersion granule was prepared by adsorbing 
the melt of the drug and poloxomer 188 onto the aerosil followed by direct 
compression with polyethylene oxide to obtain an solid dispersion loaded 
sustained release matrix tablets. This study concluded that a combination of 
solid dispersion techniques using surface adsorption and sustained release 
concepts is a promising approach to control the release rate of a poorly water 
soluble drug in a pH independent manner.  
 R.Kumaravelrajan et al.,39 had developed a prototype design for 
simultaneous drug delivery for multidrug therapy in the treatment of 
hypertension. The system composed of a middle push layer and attached 
drug layers of Nifedipine and Metoprolol resembles like a sandwich. In this 
article Polyethylene oxide of 600,000 and 8,000,000 g/mole were used as 
thickening agent in the drug layer and as an expandable hydrogel for push 
layer. Amount of polyethylene oxide and KCl had profound influence on 
drug release has been observed. Further the release of drugs was optimized 
by size of the delivery orifice, level of plasticizer and membrane thickness. 
The optimal osmotic pump was found to deliver both Nifedipne and 
Metoprolol tatarate simultaneously for extended period of time. 
 Prajapati B.G et al.,40 developed hydrophilic polymer and hydrophobic 
polymer based matrix Losartan Potassium sustained release tablet which can 
release the drug up to time of 24 hrs in predetermined rate. Influence of 
hydrophilic and hydrophobic polymer on Losartan potassium was studied. 
Administration of LP in a sustained release dosage would be more desirable 
for antihypertensive effects by maintaining the plasma concentrations of the 
drug well above the therapeutic concentration. From in vitro dissolution 
profile LP prepared with blend of HPMC K4M (67.2 mg), HPMC K200M 
(90mg) and Eudragit RSPO (112.5 mg), where drug release was about 94-
98% and also showed highest similarity factor values. 
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 Marina Koland et al., 41Mucoadhesivebuccal films of Losartan Potassium 
were prepared using Hydroxypropyl Methylcellulose and retardant polymers 
Ethyl cellulose or Eudragit RS 100. The mucoadhesive force, swelling index, 
tensile strength and percentage elongation at break was higher for those 
formulations containing higher percentage of HPMC. In vitro drug release 
studies reveal that all films exhibited sustained release in the range of 90.10 
to 97.40 % for a period of 6 hours. The data was subjected to kinetic analysis 
which indicated non-fickian diffusion for all formulations except E2. Ex vivo 
permeation studies through porcine buccal mucosa indicate that films 
containing higher percentage of the mucoadhesive polymer HPMC showed 
slower permeation of the drug for 6-7 hours. 
 Robert Gurny et al., 42in this article, the development of oral osmotic pump 
during the past 30 years had been observed. Interesting fact is that the 
production of oral osmotic pump has been doubled in the past ten years. In 
this article they have reviewed the crowded patents and manufacturing 
technologies, specific products and their clinical use. 
 Vincent Maleterre et al., 43had done this investigation to understand which 
factors have an effect on the drug delivery for modelling the drug release and 
to develop a mathematical model predictive of the drug release kinetics. For 
this study they had chosen two model drugs, Isradipine (ISR) and 
Chlophenaramine which are practically insoluble and freely soluble drugs. 
Results show that, regardless of the drug properties which do not 
significantly affect the drug delivery, the release kinetics is mainly controlled 
by four factors, (i) the PEG proportion in the membrane, (ii) the tablet 
surface area, (iii) the osmotic agent proportion and (iv) the drug layer 
polymer grade. A mathematical approach was developed to predict the drug 
delivery kinetics varying the PPOP controlling factors and helps to more 
efficiently design PPOP. 
 Karsten Mader et al.,44 the mechanism of drug release from push-pull 
osmotic systems has been investigated by Magnetic Resonance Imaging 
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using a new benchtop apparatus. The results showed that (i) hydration and 
swelling critically depend on the tablet core composition, (ii) high osmotic 
pressure developed by the push layer may lead to bypassing the drug layer 
and incomplete drug release and (iii) the hydration of both the drug and the 
push layers needs to be properly balanced to efficiently deliver the drug. 
 Vincent Malattere et al., 45carried out the study to investigate coating 
characteristics of push–pull osmotic systems using three-dimensional 
terahertz pulsed imaging (3D-TPI) and to detect physical alterations 
potentially impacting the drug release. The terahertz time-domain reflection 
signal was used to obtain information on both the spatial distribution of the 
coating thickness and the coating internal physical mapping. The results 
showed that (i) the thickness distribution of push pull osmotic system coating 
can be non-destructively analysed using 3D-TPI and (ii) internal physical 
alterations impacting the drug release kinetics were detectable by using the 
terahertz time-domain signal. The implementation of terahertz pulsed 
imaging as quality control analytical tool in the development and the 
manufacturing may represent a major step forward to improve the design, the 
scalability and potentially the quality control during the routine manufacture 
of push–pull osmotic. 
 Longxiao Liu et al., 46developed a method for preparation of monolithic 
osmotic pump tablet by modulating Atenolol solubility with acid. Tartaric 
had chosen as solubility promoter, sodium chloride as osmotic agent and 
polyvinyl pyrrollidone as retardant agent. The approach of solubility – 
modulated by acid alkali reaction might be used for the preparation of 
osmotic pump tablet for other poorly soluble drugs with alkaline or acid 
groups. The results showed that the optimal monolithic osmotic pump tablet 
was able to deliver atenolol at the rate of zero order upto 24 hours and also 
independent of release media and agitation rate. 
 Wakode R et al., 47An oral push-pull system that can deliver Pramipexole 
developed and compared with other types of osmotic delivery systems, such 
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as an asymmetric membrane coating and a dense coat with mechanical 
drilling. An optimized system was selected to study the effect of the 
concentration of a pore-forming agent such as PEG 400 and dibutyl 
phthalate, the pH of dissolution media, the effect of agitation and osmotic 
agents on drug release. The osmotic pressure generated was determined 
using a 3D3 freezing point osmometer. The drug release was found to follow 
zero order kinetics. Drug release increased with an increase in osmotic 
pressure. The developed push-pull osmotic system showed the desired once-
a-day release kinetics. 
 Longxiao Liu et al., 48proved that a bilayer core osmotic pump does not 
require laser drilling to form the delivery orifice. Bilayer consists of two 
layers (a) drug layer and (b) push layer was made with modified upper tablet 
punch. The indented tablets were coated by conventional pan coating 
process. For this study they had chosen Nifdipine as a drug model. Sodium 
chloride as osmotic agent, polyvinylpyrollidine as suspending agent, 
croscarmellose sodium as expanding agent. Ethyl cellulose with PEG 400 
was used as the coating membrane. The optimized formulation showed zero 
order release for 24 hours, independent of media and agitation. By this effort 
the preparation of bilayer core osmotic pump have simplified. 
 Shruthi Chopra et al., 49The aim of the research work was to systemically 
device a model of factors that would yield an optimized sustained release 
dosage form of an anti-hypertensive agent, Losartan Potassium, using 
response surface methodology by employing a 3-factor, 3-level Box-
Behnken statistical design. Independent variables studied were the amount of 
the release retardant polymers – HPMC K15M (X1), HPMC K100M (X2) 
and sodium carboxymethyl cellulose (X3). The dependent variables were the 
burst release in 15 min (Y1), cumulative percentage release of drug after 60 
min (Y2) and hardness (Y3) of the tablets with constraints on the Y2 = 31–
35%. Statistical validity of the polynomials was established. In vitro release 
and swelling studies were carried out for the optimized formulation and the 
data were fitted to kinetic equations. The polynomial mathematical 
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relationship obtained Y 2 ¼ 32:91 - 2:30X1 - 5:69X2 - 0:97X3 - 0:41X1X2 þ 
0:21X1X3 - 0:92X21-1:89X2 2 ðr2 ¼ 0:9944Þ explained the main and 
quadratic effects, and the interactions of factors influencing the drug release 
from matrix tablets.  The adjusted (0.9842) and predicted values (0.9893) 
of r2 for Y2 were in close agreement. Validation of the optimization study 
indicated high degree of prognostic ability of response surface   
methodology. Tablets showed an initial burst release preceding a more 
gradual sustained release phase following a non-fickian diffusion process. 
 B. Mishra et al., 50was aimed to evaluate and formulate oral osmotic pumps 
of Pentazocine HCl expected to deliver prolonged period of time with 
reduced frequency of dosing. Push-pull osmotic pump of Pentazocine HCl 
were prepared using different formulation variables such as pore diameter of 
delivery orifice, presence of surfactant, presence of osmopolymer and 
presence or absence of water soluble polymer. The results showed that the 
presence of surfactant and osmopolymer in the formulation influences the 
drug release. All formulations with different formulation variable showed 
controlled release with initial 2 hour lag phase. 
 Suresh P. Vyas et al.,51 developed an oral osmotic pump which can able to 
deliver Theophylline and Salbutamol sulphate in the multidrug therapy of 
asthma. A modified bi-layered push pull osmotic pump was developed using 
basic designs of various oral osmotic pumps. This system was developed 
initially with theophylline and optimized with two different types of 
theophylline with varying amount of hydrophilic polymer mixture in the 
upper layer and polyethylene oxide in lower layer which is expandable. 
Similarly the release of salbutamol sulphate was also optimized. Finally the 
release rate of both drugs was compared with respective marketed controlled 
release formulations. The optimized formulation was taken in order to study 
the effect of different variables. 
 Pradeep R.Vavia et al.,52 developed a controlled porosity osmotic pump of 
Pseudoephedrine, with cellulose acetate as semipermeable membrane with 
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different channelling agents like, diethylphthalate, dibutylphthalate, 
dibutylsebacate and polyethylene glycol. The drug release is directly 
proportional to the concentration of the osmotic agent used, to retard the 
release rate and to provide the desired zero order release by adding suitable 
channelling agents. In this study, diethylphthalate with plasticizer like PEG 
400 showed effective release upto 12 hours. From this article it has been 
concluded that the desired zero order release profile can be obtained by 
optimizing the drug:osmogent ratio, polymer concentration and the 
channelling agent type and concentration. 
 Sanjay Garg et al., 53 in this article they had reviewed, different types of 
oral osmotic systems and also various aspects governing drug release from 
these systems, and critical formulation factors are discussed. Osmotically 
controlled oral drug delivery systems utilize osmotic pressure for controlled 
delivery of active agent(s). Drug delivery from these systems, to a large 
extent, is independent of the physiological factors of the gastrointestinal tract 
and these systems can be utilized for systemic as well as targeted delivery of 
drugs. The release of drug(s) from osmotic systems is governed by various 
formulation factors such as solubility and osmotic pressure of the core 
component(s), size of the delivery orifice, and nature of the rate-controlling 
membrane. By optimizing formulation and processing factors, it is possible 
to develop osmotic systems to deliver drugs of diverse nature at a pre-
programmed rate.  They have concluded that by modulating the formulation 
factors it is possible to use this system to deliver drugs of diversified nature. 
 Bertil Abrahamsson et al., 54 compared the bioavailability of Nifedipine 
when administered as a hydrophilic matrix tablet (ER) and a push–pull 
osmotic pump tablet (XL) administrated after fasting, and to evaluate the 
effect of food for the hydrophilic matrix tablet. For this purpose, three 
separate studies were performed on healthy volunteers (n558) including 
gammascintigraphic monitoring of tablet erosion and localisation in the 
gastrointestinal tract for ER in one study. Both ER and XL provided almost 
constant drug delivery over 24 h, after administration under fasting 
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conditions, and bioequivalence was obtained according to 90% confidence 
intervals of the difference between formulations within 80–125% for C and 
max AUC. Food significantly increased AUC for ER but no significant 
difference was obtained between ER and XL with food with respect to extent 
of bioavailability. The rate of absorption was increased to a higher degree for 
ER than for XL, as indicated by a C which was almost twice as high for ER 
compared with XL. The results concluded that effect of food motility on rate 
of absorption. The extent of Nifedipine bioavailability appeared also 
influenced by food but a steady state would be needed to ascertain the true 
magnitude. 
 Giancarlo Santus et al., 55reviewed U.S. patents on osmotic drug delivery 
through December 1993.In this they have reviewed around 240 patents cover 
a period of a little 20 years. They had mentioned list of patents obtained right 
from the beginning by Felix Theeuwes. This review helps to guide the patent 
literature in the field of osmotic devices. 
 Gaylen M. Zenter et al.,56developed a controlled porosity osmotic pump of 
Diltiazem Hydrochloride and modulated its solubility property (reduced) for 
an extended period of 12-14 h through incorporation of controlled release 
sodium chloride elements into the core tablet formulations. Other Diltiazem 
Hydrochloride core tablets were prepared which contained the positively 
charged anion-exchange resin (poly (4-vinylpyridine). In both instances, in 
vitro Diltiazem Hydrochloride release profiles that were zero-order and pH-
independent were obtained without chemical modification of the drug. 
Release rate from devices contained resin modulated or solubility modulated 
components showed zero order release. These approaches may be applied in 
general to extend osmotic pump technology to drugs with intrinsic water 
solubility that is too high or low for conventional osmotic pump 
formulations. 
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 F.Theeuwes et al.,57 have developed oral osmotic drug delivery systems for 
Metoprololfumarate and Oxeprenolol succinate. In vitro testing confirmed 
that drug delivery corresponded closely to the theoretical release behaviour 
predicted from the physiochemical and membrane permeability 
characteristics for both Oxeprenolol and Metoprolol systems. In vitro release 
rates were also shown to be unaffected by pH, in vitro test procedures, 
dissolution media and long – term storage at different temperatures. 
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3. Scope of Work 
 In the present study, the possibility of developing an Oral Push-pull 
osmotic tablet for Losartan Potassium was explored. The system designed by using 
the basic design of Push-pull osmotic pump as push layer and pull layer consisting 
the polymer and drug respectively in the system. The investigation also aimed to use 
five different variables, the core and membrane variables. The type of osmogent, 
level of osmogent, the diameter of Orifice, the concentration of polymer and the 
thickness of the membrane are studied. These variables are optimized one after 
another by the dissolution profile.  
 The optimized formulation subjected to the test with different pH condition 
and agitational intensity. The developed systems were evaluated for the kinetics and 
pharmacopeial study as of oral tablets. 
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4. Plan of Work 
1. Review of Literature 
2. Pre-formulation 
a. Identification 
b. Drug Excipient interaction 
c. Variables to be investigated 
3. Formula development and finalization 
4. Optimization 
5. Evaluation 
   Evaluation of physical mixture  
 Bulk density 
 Angle of repose 
 Compressibility Index  
  Evaluation of Tablets 
i. Weight variation 
ii. Hardness 
iii. Thickness 
iv. Friability 
v. Drug Content (Assay) 
vi. Drug release study 
6. In-vitro characterization for optimized batch 
a. Effect of agitational intensity on drug release 
b. Effect of pH on drug release 
7. Release Kinetics 
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8. Accelerated stability studies 
 
5. Drug Profile 
5.1  Losartan Potassium58 
Losartan potassium also known as 2-butyl-4-chloro-1-[[2’-(1H-tetrazol-5-yl) 
[1,1’-buphenyl] -4-yl]- 1H-imidazole-5-methanol mono-potassium salt, is a 
competitive AT1 angiotensin II receptor antagonist and has the following formula: 
 
 
 
 
 
 
Fig.7 Chemical structure of Losartan potassium 
Molecular formula  : C22H23ClN6OK 
Molecular weight  : 461.01 
Chemical Name  : 2-butyl-4-chloro-1-[[2’-(1H-tetrazol-5-yl) [1, 1’- 
      buphenyl] -4-yl] - 1H-imidazole-5-methanol 
monopotassium 
Appearance   : A white to off-white crystalline powder. 
Solubility   : Freely soluble in water; soluble in isopropyl alcohol;
 slightly soluble in acetonitrile. 
Half-life    : 2 hours 
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Therapeutic category  : Anti-hypertensive 
Storage    : Store in a well closed container at controlled room 
 temperature. 
Losartan became the first non-peptide AT1 antagonist approved by the U.S. 
Food and Drug Administration for the clinical use. It has been approved for the 
treatment of hypertension alone or in combination with other antihypertensive 
agents. Losartan may be administered orally as its mono-potassium salt.  
5.2 Mechanism of Action58 
 Angiotensin II formed from angiotensin I in a reaction catalyzed by 
angiotensin converting enzyme, is a potent vasoconstrictor, the primary vasoactive 
hormone of the renin-angiotensin system and an important component in the 
pathophysiology of hypertension. It also stimulates aldosterone secretion by the 
adrenal cortex. Losartan and its principal active metabolite block the vasoconstrictor 
and aldosterone-secreting effects of angiotensin II by selectively blocking the 
binding of angiotensin II to the AT1 receptor found in many tissues. There is also an 
AT2 receptor found in many tissues but it is not known to be associated with 
cardiovascular homeostasis. Both losartan and its principal active metabolite do not 
exhibit any partial agonist activity at the AT1 receptor and have much greater 
affinity (about 1000-fold) for the AT1 receptor than for the AT2 receptor. In vitro 
binding studies indicate that losartan is a reversible, competitive inhibitor of the AT1 
receptor. The active metabolite is 10 to 40 times more potent by weight than losartan 
and appears to be a reversible, non-competitive inhibitor of the AT1 receptor. 
5.3 Dosage and administration59 
5.3.1 Adult Hypertensive Patients  
 Dosing must be individualized. The usual starting dose of Losartan 
potassium is 50 mg once daily, with 25 mg used in patients with possible depletion 
of intravascular volume e.g., patients treated with diuretics and patients with a 
history of hepatic impairment. Losartan potassium can be administered once or 
twice daily with total daily doses ranging from 25 mg to 100 mg. 
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 If the antihypertensive effect measured at trough using once-a-day dosing 
is inadequate, a twice-a day regimen at the same total daily dose or an increase in 
dose may give a more satisfactory response. The effect of losartan is substantially 
present within one week but in some studies the maximal effect occurred in 3-6 
weeks. No initial dosage adjustment is necessary for elderly patients or for patients 
with renal impairment, including patients on dialysis. 
5.3.2 Paediatric Hypertensive Patients ≥ 6 Years of Age 
 The usual recommended starting dose is 0.7 mg/kg once daily (up to 50 mg 
total) administered as a tablet or a suspension. Dosage should be adjusted according 
to blood pressure response. Doses above 1.4 mg/kg (or in excess of 100 mg) daily 
have not been studied in pediatric patients. Losartan potassium is not recommended 
in pediatric patients < 6 years of age or in pediatric patients with glomerular 
filtration rate < 30 mL/min/1.73 m². Oral suspension is also available for pediatrics. 
5.3.3 Hypertensive Patients with Left Ventricular Hypertrophy 
 The usual starting dose is 50 mg of Losartan potassium once daily. 
Hydrochloro-thiazide 12.5 mg daily should be added and/or the dose of Losartan 
Potassium should be increased to 100 mg once daily followed by an increase in 
hydrochlorothiazide to 25 mg once daily based on blood pressure response. 
5.3.4 Nephropathy in Type 2 Diabetic Patients 
 The usual starting dose is 50 mg once daily. The dose should be increased 
to 100 mg once daily based on blood pressure response. 
5.4  Pharmacokinetics59 
5.4.1 General 
 Losartan potassium is an orally active agent that undergoes substantial first 
pass metabolism by cytochrome P450 enzymes and converted into active carboxylic 
acid and metabolite responsible for angiotensin II receptor antagonism that follows 
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losartan treatment. The terminal half - life of losartan is about 2 hours and of the 
metabolite is about 6-9 hours. The systemic bioavailability of losartan potassium is 
approximately 33% through oral administration. About 14% of an orally-
administered dose of Losartan is converted to the active metabolite. Mean peak 
concentrations of Losartan and its active metabolite are reached in 1 hour and 3-
4hours, respectively. Losartan and its active metabolite are highly bound to plasma 
proteins, primarily albumin, with plasma free fractions of 1.3% and 0.2%. Losartan 
crosses the blood brain barrier poorly confirmed by the studies in rats.  
5.4.2 Special Populations 
Paediatric 
 Pharmacokinetic parameters after multiple doses of losartan as a tablet to 
25 hypertensive patients aged 6 to 16 years are shown in Table 4 below: 
Table: 4 Pharmacokinetic parameters determined after clinical examination 
Pharmacokinetic 
parameter 
Adults given 50 mg once 
daily for 7days N=12 
Age 6-16 given 0.7mg/kg once 
daily for 7 days N=25 
Parent Active Metabolite Parent Active Metabolite 
AUC0-24 (ng.h/mL) 442± 173 1685 ± 452 368  ± 169 1866  ± 1076 
CMAX (ng/mL) 224  ± 82 212 ± 73 141  ± 88 222  ± 127 
T1/2 (h)b 2.1  ± 0.70 7.4  ± 2.4 2.3  ± 0.8 5.6  ± 1.2 
TPEAK (h)c 0.9 3.5 2.0 4.1 
CLREN (mL/min)a 56 ± 23 20 ± 3 53 ± 33 17 ± 8 
 
5.5 Contraindications59 
 Pregnancy, lactation, children with CreatinineClearance<30 ml/min/1.73 m2 
5.6  Adverse Drug Reaction59 
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 Headache, dizziness, back pain, myalgia, respiratory tract disorders, 
asthenia / fatigue, first dose hypotension, rash, angioedema, neutropenia, GI 
disturbances, transient elevation of liver enzymes, impaired renal function, taste 
disturbances and hyperkalaemia 
5.7 Drug Interactions59 
 Hypotensive effect of losartan is potentiated by diuretics and other 
antihypertensive drugs. Risk of hyperkalaemia increases with concomitant 
Acetylcholine Esterase (ACE) inhibitors, cyclosporine, potassium-sparing diuretics 
and K supplements. Hypotensive effect may be antagonised and increased risk of 
renal impairment when used with NSAIDs. 
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6. Excipients Profile 
Polyethylene Oxide60 
Synonyms Polyox; polyoxirane; polyoxyethylene. 
Description White to off-white, free-flowing powder. Slight ammoniacal 
odor. 
Molecular formula              (CH2CH2O)n 
Chemical Name                   Polyethylene oxide 
Grades WSR N-10,80,750,3000,12K, 60K, WSR 205, 301,1105, 
Coagulant  
Molecular weight Ranges from 100000 to 8000000 
Viscosity Dynamic. 
Melting Point 65-70ºC 
Functional 
Category 
Muco-adhesive Coating agent, Tablet Binder, Thickening 
agent. 
Solubility Soluble in water and a number of common organic solvents 
such as acetonitrile, chloroform and methylene chloride. It is 
insoluble in aliphatic hydrocarbons, ethylene glycol and most 
alcohols. 
Stability Exposing to high temperature result in reduction in viscosity.                                                                
Storage It should be stored in tightly sealed containers in a cool, dry 
place. 
Incompatibilities Polyethylene oxide is incompatible with strong oxidizing 
agents. 
Applications PEO can be used as tablet binder at concentrations of 5-85%. 
The higher molecular weight grades provide delayed drug 
release via the hydrophilic matrix approach. It is used in 
immediate- or sustained matrix formulations.  
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Lactose61 
Synonyms Anhydrous Lactose NF 60M, Anhydrous Lactose NF Direct 
Tableting, Lactopress Anhydrous, lactosum, lattioso; milk 
sugar, saccharum lactis, Super-Tab Anhydrous. 
Description Lactose occurs as white to off-white crystalline particles or 
powder. Several different brands of anhydrous lactose are 
commercially available which contain anhydrous β-lactose 
and anhydrous α-lactose. Anhydrous lactose typically contains 
70–80% anhydrous β-lactose and 20–30% anhydrous α-
lactose. 
Molecular formula              C12H24O11   
Molecular weight 342.30 
Chemical Name                   O-β-D-galactopyranosyl-(1→4)-β-D-glucopyranose  
pH 4.5–7.0 for 10 % w/v aqueous solution 
Melting Point 201–202°C (for dehydrated α-lactose monohydrate) 
Functional 
Category 
Tablet and capsule diluent 
Solubility Soluble in water; sparingly soluble in ethanol (95%) and ether. 
Stability Under humid conditions (80% relative humidity and above), 
mold growth may occur. Lactose may develop of brown 
coloration on storage, the reaction being accelerated by warm, 
damp conditions. The purity of different lactose can vary and 
color evaluation may thus be important, particularly if white 
tablet are being formulated 
Storage It should be stored in well closed container  
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Incompatibilities The presence of lactose anhydrous accelerate the hydrolysis of 
the ester and amidine groups 
Applications Anhydrous lactose is widely used in direct compression and as 
a tablet and capsule filler and binder. Anhydrous lactose can 
be used with moisture-sensitive drugs. 
 
Colloidal Silicon Dioxide62 
Synonyms Aerosil, Colloidal silica, Fumed silica, Light anhydrous silicic 
acid, Silicic anhydride; Silicon dioxide fumed 
Description It is submicroscopic fumed silica with a particle size of about 
15 nm. It is a light, loose, bluish-white-colored, odorless, 
tasteless, non-gritty amorphous powder. 
Molecular formula              SiO2 
Molecular weight 60.08 
Chemical Name                   Silica
pH 3.5–4.4 (4% w/v aqueous dispersion) 
Functional 
Category 
Adsorbent, Anticaking agent, Emulsion stabilizer; Glidant; 
suspending agent, Tablet Disintegrant, Thermal stabilizer, 
Viscosity-increasing agent. 
Solubility Practically insoluble in organic solvents, water, and acids, 
except hydrofluoric acid; soluble in hot solutions of alkali 
hydroxide. Forms a colloidal dispersion with water. 
Stability Colloidal silicon dioxide is hygroscopic but adsorbs large 
quantities of water without liquefying. 
Storage It should be stored in a well-closed container. 
Incompatibilities Incompatible with diethylstilbestrol preparations 
Applications Its small particle size and large specific surface area give it 
desirable flow characteristics. It is also used as a thickening 
agent for topical preparations. 
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Talc63 
Synonyms Magil osmanthus, Magsil Star; powdered talc; purified much 
chalk, Purtalc, soapstone, Steatite 
Description It is very fine, white to grayish-white. Colored odorless, 
impalpable, unctuous, crystalline powder.  
Molecular formula              Mg6(Si2O5)4(OH)4 
Chemical Name                   Talc
pH 7.0 – 10.0 for a 20 % aqueous dispersion. 
Melting Point  
Functional 
Category 
Talcing agent, glidant; tablet and capsule diluent; tablet 
capsule lubricant 
Solubility Insoluble in water, organic solvent, dilute acid & alkalis. 
Stability Talc is a stable material and may be sterilized by heating at 
160°C for not less than 1 hour. It may also be sterilized by 
exposure to ethylene oxide or gamma irradiation. 
Storage It should be stored in a well-closed container in a cool, dry 
place. 
Incompatibilities Incompatible with quaternary ammonium compounds 
Applications It is widely used in oral solid dosage forms as a glidant & 
diluent. It is used as a dusting powder in topical use. 
Additionally used to clarify liquids and mainly used in food 
and cosmetics products because of its lubricant properties. 
 
 
 
 
 
Magnesium Stearate64 
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Synonyms Magnesium octadecanoate, Octadecanoic acid,  Magnesium 
salt of Stearic acid 
Description It occurs as a fine, white, precipitated or milled  impalpable 
powder with a faint odor and a characteristic taste 
Molecular formula              C36H70MgO4 
Molecular weight 591.34 
Chemical Name                   Octadecanoic acid magnesium salt 
Melting Point 117 – 150ºC 
Functional 
Category 
Tablet and capsule lubricant 
Solubility Practically insoluble in ethanol, ether and water; Slightly 
soluble in warm benzene and warm Ethanol (95%) 
Stability It is a stable material 
Storage It should be stored in a well-closed container, in a cool, dry 
place. 
Incompatibilities Magnesium stearate cannot be used in products containing 
aspirin, some vitamins, and most alkaloidal salts Incompatible 
with strong acids, alkalis and iron salts. 
Applications It is primarily used as a lubricant in tablet and capsules in 
concentrations between 0.25 % and 5 %. It is widely used in 
cosmetic and food  industry  
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7. Materials and Methods 
7.1. Materials and Equipments Used 
S.No. Material Used Source Uses 
1 Losartan potassium Madras 
pharmaceuticals 
(P) Ltd., 
Anti-Hypertensive 
2 Polyethylene Oxide SigmaAldrich Ltd.,  Matrix Polymer 
3 Lactose  LobaChemie Ltd., Diluent cum Osmotic agent 
4 Magnesium Stearate  LobaChemie Ltd., Diluent 
5 Colloidal Silicon Dioxide LobaChemie Ltd., Adsorbent, Suspending agent 
6 Talc LobaChemie Ltd., Lubricant 
  
 Equipments Used 
S.No. Instruments Brand 
1 Electronic weighing balance 
 (Capacity: 10mg – 200mg) 
Axis, India  
2 Vernier callipers Mitutoyo, Japan 
3 Hardness tester Monsanto, China 
4 Tablet dissolution apparatus Electrolab, India 
6 UV Spectrophotometer  Shimadzu UV 1061, Japan 
7 Compression machine-8 station Cadmach, India 
8 FT-IR Spectrophotometer Shimadzu corp., Japan. 
9 pH meter Digisun Electronics, India 
10 Hot air oven Pathak electrical works, India 
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7.2 Experimental Methods 
7.2.1 Preformulation Studies 
 Preformulation studies are the first steps which focus on the physicochemical 
properties of new compound that could not affect drug performance and development of 
an efficacious dosage from. The objective of preformulation study is to develop a portfolio 
of information about the drug substance, so that this information is useful to develop a 
formulation.  
 Preformulation can be defined as investigation of physical and 
preformulation of drug substance alone and when combined with excipients. 
Preformulation investigations are designed to identify those physicochemical 
properties and excipients that may influence the formulation design, method of 
manufacture, and pharmacokinetic-biopharmaceutical properties of the resulting 
product. 
7.2.2 Drug Excipient Interaction studies 
 Drug excipient interaction study was performed in pre-formulation stage to 
assess the possible incompatibilities of the Active Pharmaceutical Ingredients with 
the excipients in the process of development of a solid dosage form. This interaction 
can be found out by performing thermal analysis of the drug and excipients using 
Differential Scanning Calorimetery (DSC) at the recommended conditions. The 
variations in the DSC thermograms of the pure drug were compared with the DSC 
thermograms of the drug and excipient mixture. The incompatibilities can be 
identified by variations in the corresponding enthalpies. The DSC analysis was 
performed in heat flow rate of 10ºC/ min in the temperature range from                    
30 ºC to 450 ºC. 
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7.2.3  Raw Material Analysis 
Appearance   : A white to off-white crystalline powder 
Solubility   : Freely soluble in water; Soluble in isopropyl alcohol;
     slightly soluble in acetonitrile. 
Assay                                : 100.0mg of Losartan Potassium working standard was   
accurately weighed and transformed into 100ml 
volumetric flask and the volume is made up with 
purified water. Take 1ml of the above solution and 
transfer into 100ml volumetric and make up the 
volume with purified water and mix. 
Identification Test : Infrared spectra, Heavy metals, sulphated ash and loss on 
 Drying were carried out as per IP 2010. 
7.2.4 Pre-Compression Parameters 
7.2.4.1  Bulk Density65 
 The powder sample (blend) under test was screened through sieve #18 and 
the sample equivalent to 20g was accurately weighed and filled in a 100ml 
graduated cylinder and the powder was leveled and the unsettled volume (V0) was 
noted. The bulk density was calculated in g/cm3 by the formula, 
 Bulk density (ρ0) = 
0V
M
 
where,
 
 M = mass of powder taken 
 V0= apparent untapped volume 
7.2.4.2  Angle of Repose65 
 Angle of repose of the granules was determined by the height cone method. 
A funnel was fixed to a desired height and granules were filled in it. They were 
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allowed to flow down on a graph paper fixed on a horizontal surface and angle of 
repose was calculated using the formula given in equation, 
 Tan θ = 
D
h2
 
where, h and Dare height and diameter of the pile respectively. The 
specifications of angle of repose were given in Table: 5. 
Table: 5 Flow of Powders with Angle of Repose values 
Angle of repose (degrees) Type of flow 
< 20 Excellent 
20-30 Good 
30-34 Passable* 
> 40 Very poor 
                       *May be improved by glidant 
7.2.4.3  Compressibility Index65 
 Based on the poured density and tapped density, the percentage 
compressibility of the granules was computed using the Carr’s compressibility index 
by the formula and the Carr’s index value and its specifications are given in                  
Table: 6.𝐶𝑎𝑟𝑟’𝑠 𝑖𝑛𝑑𝑒𝑥 (%) =  𝑝𝑜𝑢𝑟𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦−𝑡𝑎𝑝𝑝𝑒𝑑 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 
𝑃𝑜𝑢𝑟𝑒𝑑 𝐷𝑒𝑛𝑠𝑖𝑡𝑦  𝑋 100 
 Table: 6 Flow of Powders with Carr’s Index values 
Carr’s index (%) Type of flow 
5-15 Excellent 
12-16 Good 
18-21 Fair to passable 
23-35 Poor 
33-38 Very poor 
> 40 Extremely poor 
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7.3  Formulation of Tablets 
 The core tablet consists of bilayer, the upper drug layer and lower push 
layer which compressed directly into the tablet form. The push layer was first filled 
in the die cavity and compacted using 16/32 inch deep concave punches. Then the 
drug layer is laid into the die cavity and compacted. Finally the bilayer composition 
was compressed with maximum pressure. The compression was carried out by using 
rotary tablet compression machine with 8 stations. The formula for drug layer and 
push layer is given in Table: 7. 
Table: 7   Formula for Drug layer and push layer 
Drug Layer 
Ingredients* 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Drug 100 100 100 100 100 100 100 100 100 100 100 100 
Aerosil 5 5 5 5 5 5 5 5 5 5 5 5 
Talc 16 16 16 16 16 16 16 16 16 16 16 16 
Magnesium Stearate 5 5 5 5 5 5 5 5 5 5 5 5 
Lactose - 50 100 150 100 100 100 100 100 100 100 100 
Nacl 100 - - - - - - - - - - - 
Push Layer 
Ingredients* 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
PEO 100 100 100 100 100 100 100 200 50 200 200 100 
Aerosil 5 5 5 5 5 5 5 5 5 5 5 5 
Talc 16 16 16 16 16 16 16 16 16 16 16 16 
Magnesium Stearate 5 5 5 5 5 5 5 5 5 5 5 5 
Lactose - 50 100 150 100 100 100 100 100 100 100 100 
Nacl 100 - - - - - - - - - - - 
*All ingredients were taken in milligram 
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7.3.1 Coating and Drilling 
 The bilayer tablets were coated with a 4% w/w cellulose acetate in acetone 
semipermeable membrane using pan coater. The coated tablets were drilled 
mechanically with different orifice diameter by using different drill bits.  
 The coating conditions are indicated as follows: 
 Pan specification :  stainless steel, spherical, 300 mm diameter 
 Pan rotating  :  18 rpm. 
 Spray rate  :  3ml/min. 
 Drying  :  by a heat gun 
 Coated tablets were dried over night at 40ºC in a hot air oven. The tablets 
were obtained thickness by concurrent coating with the coating solution.  
7.4  Optimization of Variables 
 Five variables were taken into consideration to optimize the release of drug 
from the osmotic system. The five variables taken for optimization were osmogent 
type, osmogent concentration, orifice diameter, polymer concentration and 
membrane thickness. These four parameters were taken for optimization as these 
have great influence on drug release from the osmotic system. Optimization was 
carried out based on the in vitro drug release profile for each parameter.  Table: 8 
represents the optimization process based on the drug release profile. 
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Table: 8 Optimization Process for independent formulation variables 
Formulation Osmogent Type 
Osmogent 
Concentration (mg) 
Orifice diameter 
(µm) 
Polymer Concentration 
(mg) 
Coating Thickness 
(%) 
F1 Sodium Chloride 200 850 100 12 % 
F2 Lactose 200 850 100 12 % 
F3 Optimized 100 850 100 12 % 
F4 Optimized 300 850 100 12 % 
F5 Optimized Optimized 450 100 12 % 
F6 Optimized Optimized 550 100 12 % 
F7 Optimized Optimized 250 100 12 % 
F8 Optimized Optimized Optimized 200 12 % 
F9 Optimized Optimized Optimized 50 12 % 
F10 Optimized Optimized Optimized Optimized 10% 
F11 Optimized Optimized Optimized Optimized 15% 
F12 Optimized Optimized Optimized Optimized Optimized 
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7.4.1 Effect of Osmogent Type 
 To investigate the effect of osmotic agent type on the drug release two 
different types of osmotic agent were chosen for this study. Sodium chloride and 
lactose were selected as models for this investigation. The two osmotic agents were 
taken in same concentration and the release of drug from these two systems was 
investigated. The osmotic agents were taken in both the upper and lower layer of the 
tablet. The formula for the F1 and F2 formulation were given in the Table: 7. The 
drug releases of both the formulations were carried out as the same procedure. 
7.4.2 Effect of Osmogent Concentration on Drug Release 
 In order to study the effect of osmogent concentration on the drug release, 
tablets with different concentrations of osmogent were prepared. The osmogent 
concentrations taken for investigation were100, 200 and 300 mg being all other 
variables were kept constant. The percentage releases of the drug of different 
formulations were recorded.  
7.4.3 Effect of Delivery Aperture on Drug Release 
 To investigate the effect of aperture on the drug release, the coated tablets 
were drilled manually with different orifice sizes 250,450, 550 and 850 µm. The 
percentage release of the drug was studied and compared. 
7.4.4 Effect of Polymer Concentration on Drug Release 
 To study the effect of polymer concentration on drug release, tablets with 
different concentration of polyethylene oxide corresponding to the drug were 
prepared. Different polymer concentration taken into account for this study was 
50mg, 100mg and 200mg. The tablets with three different polymer concentrations 
were prepared and coated being other variables were kept constant. 
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7.4.5 Effect of Membrane Thickness on Drug Release 
 The effect of coating thickness, the core tablets were coated with three 
different level of 4% w/w cellulose acetate in acetone. The coating thickness is 
increased to three levels of tablet weight gain, such as 10, 12 and 15% w/w of the 
core tablet. 
7.5 Evaluation of Tablets 
 The compressed tablets were evaluated for the following tests and the 
results are tabulated in Table: 11. 
7.5.2  Thickness 
 The tablet thickness is an important factor which is to be investigated 
during packaging. At constant compressive load, thickness of tablets varies with 
changes in die fill, particle size distribution and packing of the particle mix being 
compressed. Tablet thickness of all the formulations was measured using 
verniercalipher and the reading was recorded. 
7.5.3  Hardness 
 Hardness is defined as the force required for breaking a tablet in a diametric 
compression test. This parameter is important to know that the tablet has sufficient 
strength to withstand mechanical shocks of handling in manufacturing, packaging 
and shipping. Tablet hardness was measured using a Monsanto hardness tester. 
7.5.4  Assay of Losartan Potassium by UV-Spectrophotometer 
Standard Preparation 
 100.0mg of Losartan Potassium working standard was accurately weighed 
and transformed into 100ml volumetric flask and the volume is made up with 
purified water. Take 1ml of the above solution and transfer into 100ml volumetric 
and make up the volume with purified water and mix. 
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Sample Preparation 
 Twenty tablets were weighed and powdered. 110 mg of powdered tablet 
(equivalent to 100 mg of Losartan Potassium) weighed and transferred into 100ml 
volumetric flask and the volume is made up with purified water. Take 5ml of the 
above solution and transfer it into 100ml volumetric and make up the volume with 
purified water and mix. The solution was filtered through 0.45 µm membrane filter 
and measured with UV-Spectrophotometer at 235 nm. 
Calculation 
Asam W1 1 100 100 P Avg. Wt.  
---------- X ---------- X ---------- X ---------- X ---------- X ---------- X ---------- X 100 
Astd 100 100 W2 5 100 L.C  
 
Asam   Absorbance of the sample preparation 
Astd   Absorbance of the standard preparation 
W1   Weight in mg of Losartan potassium working standard 
W2   Weight in mg of Losartan potassium sample. 
P   Percentage purity of Losartan Potassium of working standard 
L.C   Label claim of Losartan potassium. 
Avg. Wt   Average weight of tablet. 
7.5.5  In vitro Drug Release 
Chemicals and Reagents 
1. Purified water. 
2. Potassium dihydrogen orthophosphate. 
3. Sodium hydroxide. 
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Dissolution test Condition 
 Model  : Electrolab Dissolution  
 Apparatus  : USP type II (paddle) 
 Medium  : pH 6.8 phosphate buffer 
 Medium Volume : 900ml 
 Temperature  : 37ºC 
 Rotation speed : 100 rpm 
 Sampling time : 2, 4, 6, 8, 12 and 24hour. 
UV Parameters 
 Path Length  : 1mm 
 Wave length  : 235 nm 
 Mode  : Photometric 
 Preparation of pH 6.8 Phosphate Buffer 
 6.8g of Potassium Di-hydrogen Orthophosphate and 5 M of sodium 
hydroxide was mixed in purified water. Then the solution is made up to 1000ml with 
purified water. The pH of the solution was adjusted to 6.8 ± 0.05. 
 Standard Preparation 
 50.0mg of Losartan Potassium working standard was accurately weighed 
and transformed into 100ml volumetric flask and the volume is made up with 
purified water. Take 1ml of the above solution and transfer into 100ml volumetric 
and make up the volume dissolution medium. 
 Sample Preparation 
 Dissolution apparatus was set as per above parameters. One tablet was 
placed in each of the six dissolution basket and the apparatus was allowed to attain 
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the set protocol. The dissolution apparatus was operated. At the end of specified 
sampling time, 5ml of the dissolution medium were withdrawn and filtered through 
0.45µm.After each sampling time the medium was replaced with fresh solution.1ml 
of the filtrate from each vessel was separately diluted to 25 ml with dissolution 
medium. The absorbance of the drug was measured at 235 nm. 
 The percentage of drug release was calculated by using the formula 
% Drug Release = 
Asam  W1  1  900  P   
------ X ------- X ------ X ----- X ------ X 100 
Astd  100  100  W2  100   
  
Asam   Absorbance of the sample preparation 
Astd   Absorbance of the standard preparation 
W1   Weight in mg of Losartan potassium working standard 
W2   Weight of one tablet. 
P   Percentage purity of Losartan Potassium of working standard 
L.C   Label claim of Losartan potassium. 
7.5.6 Effect of Agitational Intensity 
 In order to investigate the effect of agitational intensity of the release 
media, drug release of the optimized formulation were carried out in the dissolution 
apparatus USP II at different rotational speeds. The rotational speeds taken for the 
investigation were 50, 100 and 150 rpm. Samples were withdrawn at 2, 4, 6, 8, 12 
and 24 hour of different time intervals. Collected samples were filtered and 
analysed. The percentage cumulative drug release of the optimized formulation at 
various rotational speeds was plotted and the results were compared. 
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7.5.7 Effect of pH on Drug Release 
 In order to study the effect of pH and to assure a reliable performance of 
the developed formulations independent of pH, release studies of the optimized 
formulations were conducted in media of different pH 1.2, pH 6.8 and pH change 
method in which the release media was simulated gastric fluid for first 2 h and then 
followed by pH 6.8. The samples of five millilitres were withdrawn at pre-
determined intervals and analysed after filtration. The percentage cumulative drug 
release of optimized formulations at various pH was plotted and compared. 
7.6 Release Kinetics 
 The kinetics of drug release for the controlled release osmotic pump tablet 
was studied. The in vitro dissolution data of the optimized formulation was fitted 
into various kinetic models. The first order equation describes that the release is 
concentration dependent. According to Higuchi model, the drug release from 
insoluble matrix is directly proportional to square root of time and is based on 
Fickian diffusion. Drug release data obtained was applied to different drug release 
models in order to establish the drug release mechanism and kinetics. Best goodness 
of fit test (R2) was taken as criteria for selecting the most appropriate model. 
7.6.1   Zero Order Equation 
 The graph was plotted as percentage drug released against time in hours. 
Zero order kinetics can be expressed by equation (5) 
 C = K0t        (5)    
where, 
 K0 = Zero order constant in concentration/time. 
 t = Time in hours. 
 The graph would give a straight line with a slope equal to K0 and intercept 
the origin of the axis. 
 69 
 
7.6.2  First Order Kinetics 
 The graph was plotted as log % cumulative drug remaining against time in 
hours. The equation for first order kinetics is given in equation (6) 
Log C = Log C0 – Kt / 2.303  (6) 
Where, 
C0 = Initial concentration of drug 
K = First order constants 
t = Time in hours. 
 
7.6.3  Higuchi Kinetics  
 The graph was plotted as % Cumulative drug released against square root 
of time. Higuchi kinetics can be calculated by equation (7) 
 Q = Kt1/2        (7)  
where, 
 K = constant reflecting design variable system 
 t = time in hours. 
 Hence drug release rate is proportional to the reciprocal of square root of 
time. If the plot yields a straight line and the slope is one, then the particular dosage 
form is considered to follow Higuchi kinetics of drug release. 
7.6.4  Hixson – Crowell equation 
Hixson – Crowell equation is plotted to evaluate the drug release with changes in 
the surface area and the diameter of particles. The graph was plotted by cube root of % drug 
remaining against time in hours. 
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Q01/3 – Qt1/3 = KHC Xt     (8) 
Where, 
Qt = Amount of drug released in time‘t’. 
Q0 = Rate constant for Hixson – Crowell equation. 
 
7.6.5  Koresmeyer – Peppas equation 
Peppas equation is plotted by using log cumulative % of drug released 
against time. 
Mt /Mα = Ktn       (9) 
  Log Mt /Mα = log K + n logt   (10) 
Where, 
Mt / Mα = Fraction of drug released at time’t’. 
T = Release time 
K = kinetic constant (incorporating structural and geometric characteristics of 
preparation). 
n = Diffusional exponent indicative of the mechanism of drug release. 
• If n value is 0.5 or less, the release mechanism follows “fickian diffusion” 
and higher values of 0.5 < n > 1 for mass transfer follow a non-fickian model 
(anomalous transport).  
• The drug release follows zero-order drug release and case II transport if the 
value is 1. 
• For the values of n higher than 1, the mechanism of drug release is regarded 
as super case II transport. This model is used to analyse the release of 
pharmaceutical polymeric dosage forms when the release mechanism is not 
known or more than one type of release was involved. The n value could be 
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obtained from slope of the plot of log cumulative % drug released Vs log 
time. 
 
7.7.  Stability Studies 
The purpose of stability testing is to provide evidence on how the quality of a drug 
substance or drug product varies with time under the influence of a variety of environmental 
factors such as temperature, humidity and light and to establish a retest for the drug 
substance or a shelf life for the drug product and recommended storage conditions. Stability 
of a drug is defined as the ability of a particular formulation, in a specific container, to 
remain within its physical, chemical, therapeutical and toxicological specifications. The 
following storage conditions for stability studies are followed as per ICH guidelines. 
 
Table: 9 Storage conditions for stability studies as per ICH guidelines 
Type of Study Storage conditions 
Long term 25ºC±2ºC / 60% RH ± 5%RH 
Intermediate 30ºC±2ºC / 65% RH ± 5%RH 
Accelerated 40ºC±2ºC / 75% RH ± 5%RH 
 
The final tablets were subjected to accelerated stability studies. The tablets 
were kept in stability chamber. The samples were analyzed at 0, 1 and 2 months’ 
time points. The data was analysed for any significant changes from the initial data. 
The following tests were performed 
i. Test for physical parameters. 
ii. Assay 
iii. In-vitro dissolution study.  
The conditions to carry out stability studies were given in the Table 9. 
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8.0 Results 
8.1  Preformulation Studies 
8.1.1  Drug Excipient Compatibility Studies 
 Conditions 
 Heat Flow rate  : 10ºC / min. 
 Temperature range  : 30 ºC - 450 ºC 
 The drug excipient interaction was investigated by Differential Scanning 
Calorimetry, one of the fast evaluating methods to study the drug excipient 
interactions. The Fig.10 and Fig.11 depicts the thermograms of the pure Losartan 
Potassium and Losartan Potassium with the excipients expressing that there was no 
significant variations was observed during the Thermal analysis proved that there 
was no interaction between the drug and the excipients. 
Table: 10 Raw Material Analyses 
Tests Specifications Observation 
Description A white to off-white crystalline 
powder 
Off-white crystalline 
powder 
Solubility Freely soluble in water, soluble in 
isopropyl alcohol, slightly soluble 
in acetonitrile 
Complies 
Identification The Infrared spectrum of the should 
match with the standard spectrum Complies 
Heavy metals NMT 20 ppm Complies 
Assay NLT 98.0 % and NMT 102% 99.8% 
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Conditions:  RT 40ºC ± 2ºC and RH 75% ± 5% 
Table: 11 Physical Observations 
Drug + Excipient Parameter 
Observation 
Comments Initial After 30 
days 
Losartan Potassium + 
PEO 
Colour 
Change 
No colour 
change 
No colour 
change 
Compatible 
Losartan Potassium + 
Lactose 
Colour 
Change 
No colour 
change 
No colour 
change 
Compatible 
Losartan Potassium + 
Aerosil 
Colour 
Change 
No colour 
change 
No colour 
change 
Compatible 
Losartan Potassium + 
Magnesium Stearate  
Colour 
Change 
No colour 
change 
No colour 
change 
Compatible 
Losartan Potassium + 
Talc 
Colour 
Change 
No colour 
change 
No colour 
change 
Compatible 
Losartan Potassium + 
Cellulose Acetate 
Colour 
Change 
No colour 
change 
No colour 
change 
Compatible 
Losartan Potassium + 
Acetone 
Colour 
Change 
No colour 
change 
No colour 
change 
Compatible 
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Fig.8 Infrared spectrum of Losartan potassium working standard 
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Fig.9 Infrared spectrum for mixture of Losartan Potassium and Polyethylene Oxide 
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Fig. 10 DSC Thermogram of pure Losartan Potassium 
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Fig.11 DSC Thermogram of Losartan Potassium with Excipients. 
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Table: 12 Evaluation of Physical mixtures 
Formulation Code Bulk Density g/ml 
Tapped Density 
g/ml 
Compressibility Index % Angle of Repose 
F1 0.42 ± 0.02 0.49 ± 0.04 14.28 ± 0.10 24.50 ± 0.16 
F2 0.44 ± 0.04 0.51 ± 0.06 13.72 ± 0.04 26.68 ± 0.23 
F3 0.43 ± 0.06 0.50 ± 0.02 14.01 ± 0.03 25.54 ± 0.45 
F4 0.43 ± 0.05 0.49 ± 0.03 14.28 ± 0.05 28.56 ± 0.13 
F5 0.41 ± 0.03 0.48 ± 0.05 14.31 ± 0.03 25.87 ± 0.38 
F6 0.43± 0.06 0.49 ± 0.06 12.24 ± 0.08 28.09 ± 0.41 
F7 0.41 ± 0.09 0.49 ± 0.02 14.76 ± 0.04 25.34 ± 0.26 
F8 0.44 ± 0.06 0.50 ± 0.03 12.10± 0.06 27.56± 0.38 
F9 0.42 ± 0.04 0.50 ± 0.02 13.56 ± 0.03 26.54 ± 0.24 
F10 0.43 ± 0.06 0.49 ± 0.04 12.67 ± 0.07 27.80 ± 0.19 
F11 0.42 ± 0.05 0.48 ± 0.03 14.52 ± 0.03 24.17 ± 0.33 
F12 0.42 ± 0.06 0.49 ± 0.06 14.08 ± 0.02 26.16 ± 0.46 
                                                                                                                                          Mean ± SD (n = 6)
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8.2 Evaluation of Tablets 
Table: 13 Evaluation of Uncoated Tablets 
Formulation code 
Thickness* 
(mm) 
Hardness* 
Kg/cm2 
Assay# 
(%) 
F1 5.02 ± 0.032 6.02 ± 0.065 99.78 ± 0.552 
F2 5.22 ± 0.023 6.63 ± 0.043 99.23 ± 0.412 
F3 5.36 ± 0.016 6.53 ± 0.098 98.78 ± 0.312 
F4 4.89 ± 0.026 6.32 ± 0.023 101.34 ± 0.167 
F5 5.86 ± 0.015 6.32 ± 0.045 99.78 ± 0.341 
F6 5.41 ± 0.043 6.67 ± 0.021 100.76 ± 0.213 
F7 5.45 ± 0.021 6.45 ± 0.067 98.59 ± 0.541 
F8 4.94 ± 0.085 6.43 ± 0.089 98.64 ± 0.257 
F9 5.34 ± 0.021 6.45 ± 0.031 99.21 ± 0.364 
F10 5.54 ± 0.045 6.00 ± 0.041 99.65 ± 0.421 
F11 5.23 ± 0.034 5.94 ± 0.054 98.32 ± 0.231 
F12 4.92 ± 0.078 6.02 ± 0.032 98.54 ± 0.478 
     * Mean ± SD (n = 6)   #Mean ± SD (n = 3) 
8.3  Optimization of variables 
8.3.1  Effect of Osmogent Type 
 The release rate of the system containing two different osmotic agents was 
studied and the results are recorded in Table: 14.  Fig. 12 shows the comparison of 
release rate between the two types of osmotic agents. 
8.3.2  Influence of Osmotic agent Concentration on Drug Release 
 The effect of osmotic agent concentration on drug release was studied and 
the results are tabulated in Table: 15. The osmotic agent of three different 
concentration chosen for the study was completed and the results are compared.   
Fig. 13 illustrates the release rate of the drug from the system. 
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8.3.3  Influence of Orifice diameter on Drug release 
 The effect of orifice diameter was investigated by drilling orifice with 
different diameter. The results were recorded and the release rates of drug through 
different orifices were compared. The percentage drug release for corresponding 
delivery orifices were given in Table: 16. The comparison of the release is shown in 
the Fig. 14. 
8.3.4  Effect of polymer concentration on drug release 
 The effects of polymer concentration on drug release were inspected and 
the results were given in the Table: 17.  The polymer present in the push layer 
which is of high molecular weight is act as a swelling agent which able to control 
the release of the drug for a prolonged period of time. The hydrogel formation of the 
polymer at the end of dissolution was confirmed by latex formation. The results 
were compared and represented in Fig. 15. 
8.3.5  Influence of Membrane Thickness on Drug Release 
 The effect of membrane thickness on drug release was investigated and the 
results were given in the Table: 18. The drug release is inversely proportional to the 
membrane thickness. The results were shown in Fig. 16. 
8.3.6 Effect of Agitational Intensity 
 The release from the optimized formulation is found to be independent of 
the agitational intensity. The graph plotted in Fig. 17 shows that there is no 
significant difference in drug release under different agitations. Table: 19 represent 
the influence of agitational intensity on drug release. 
8.3.7 Effect of pH on Drug Release 
 Figure showed release of drug from an optimized formulation in pH (1.2); 
pH change method and pH 6.8 respectively. The results showed that the release 
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Fig.12 In vitro dissolution profile of Losartan from various Osmogent
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profile is same in all the media, hence the optimized formulation showed 
independent release depicted in Fig. 18.   
Table: 14 Release of Losartan from different type of Osmogent. 
Time (h) 
Osmogent Type 
Sodium Chloride Lactose 
0 0.00 ± 0.00 0.00 ± 0.00 
2 27.16 ± 0.05 37.54 ± 0.14 
4 35.74 ± 0.65 45.54 ± 0.34 
6 46.29 ± 0.23 56.08 ± 0.21 
8 68.6 6± 0.37 62.43 ± 0.34 
12 93.37 ± 0.45 76.21 ± 0.18 
24 - 98.23 ± 0.54 
Mean ±SD (n = 6) 
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Fig.13 In vitro dissolution profile of Losartan from various concentrations
 of Osmogent
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Table: 15 Influence of Osmotic agent concentration on drug release 
Time (h) 
Osmotic agent Concentration 
F3 (100mg)  F2 (200mg)   F4 (300mg)  
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
2 8.23 ± 0.30 14.23 ± 0.43 28.76 ± 0.43 
4 14.56 ± 0.23 24.50 ± 0.36  48.27 ± 0.12 
6 26.43 ± 0.50 36.21 ± 0.46 68.20 ± 0.36 
8 37.65 ± 0.42 48.20 ± 0.67  77.23 ± 0.45 
12 48.21 ± 0.32 66.54 ± 0.43 90.43 ± 0.32 
24 70.32 ± 0.68 97.64 ± 0.51 - 
        Mean ± SD (n = 6) 
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Fig.14  Effect of Orifice Diameter on Drug release
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Table: 16 Influence of Orifice diameter on  drug release  
Time (h) 
Orifice diameter 
250 µm 450 µm 550 µm 850 µm 
0 0.00± 0.00 00.00 ± 0.00 00.00 ± 0.00 00.00 ± 0.00 
2 10.23 ± 0.13 26.42 ± 0.43 39.63 ± 0.34 45.21 ± 0.45 
4 25.43 ± 0.25 37.21 ± 0.41 51.43 ± 0.43 58.43 ± 0.39 
6 36.21 ± 0.43 46.32 ± 0.54 67.42 ± 0.23 67.42 ± 0.32 
8 44.43 ± 0.46 59.17 ± 0.34 78.21 ± 0.46 82.24 ± 0.21 
12 55.24 ± 0.21 78.32 ± 0.12 89.32 ± 0.41 90.12 ± 0.12 
24 72.76 ± 0.45 98.21± 0.23 96.43 ± 0.25 - 
        Mean ± SD (n = 6) 
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Fig.15 Influence of polymer concentration on Drug release
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Table: 17 Effect of polymer concentration on drug release 
Time (h)  
Polymer Concentration 
F9 (50mg) F5 (100mg) F8 (200mg) 
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
2 22.12 ± 0.21 12.32 ± 0.25 9.32 ± 0.25 
4 42.12 ± 0.28 26.32 ± 0.21 19.43 ± 0.53 
6 58.21 ± 0.21 39.62 ± 0.89 24.41 ± 0.43 
8 65.67 ± 0.39 46.32 ± 0.40 35.62 ± 0.74 
12 93.21 ± 0.41 62.21 ± 0.81 54.23  ± 0.41 
24 98.12 ± 0.32 98.45 ± 0.32 70.02 ± 0.25 
Mean ± SD (n = 6) 
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Fig.16  Effect of coating thickness on drug release
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Table: 18 Influence of membrane thickness on Drug release 
Time (h) 
Membrane Thickness 
10%w/w 12% w/w* 15% w/w 
0 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 
2 18.21 ± 0.45 12.32 ± 0.76 9.21± 0.54 
4 36.56 ± 0.39 28.28 ± 0.56 21.43± 0.47 
6 48.43 ± 0.26 38.08± 0.76 33.54 ± 0.43 
8 62.36 ± 0.54 52.34 ± 0.21 49.36 ± 0.61 
12 90.32± 0.26 68.43 ± 0.15 58.43 ± 0.43 
24 - 95.32 ± 0.24 76.43 ± 0.54 
         Mean ± SD (n = 6) 
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Fig.17  Effect of agitational intensity on drug release
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Table: 19 Effect of agitational intensity on drug release 
 
Time (h) 
% Cumulative percentage drug release 
50 rpm 100 rpm 150 rpm 
0 0 0 0 
2 8.02± 0.21 10.54± 0.12 9.12  ± 0.34 
4 19.21 ± 0.38 20.21± 0.43 19.21 ± 0.32 
6 20.21 ± 0.19 28.43± 0.54 26.03 ± 0.21 
8 28.21 ± 0.67 39.54± 0.21 36.21 ± 0.56 
12 39.34± 0.54 56.21± 0.48 55.32± 0.65 
24 93.21± 0.32 99.21± 0.29 98.21± 0.32 
   Mean ± SD (n = 6) 
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Fig.18  Effect of pH on drug release
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Table: 20 Influence of pH on drug release 
Time (h) pH 1.2 pH 6.8. pH change method 
0 0.00±0.00 0.00±0.00 0.00±0.00 
2 8.21 ± 0.32 10.12±0.34 12.21±0.45 
4 16.00±0.00 19.43±0.00 18.45±0.12 
6 22.45±0.12 29.00±0.00 26.00±0.23 
8 32.43±0.12 38.43±0.34 35.12±0.44 
12 45.21±0.32 55.23±0.32. 49.21±0.54 
24 93.43±0.21 98.54±0.21 96.21±0.32 
        Mean ± SD (n = 6) 
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8.4  Release Kinetics  
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19 Zero Order Kinetics 
Fig. 20 First Order Kinetics 
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Fig.21 Higuchi Kinetics 
  
Table: 21 Release Kinetics data to fit various mathematical models 
Cumulative 
(%) Release Q Time ( t ) 
root 
(t) 
Log        
(%) 
Release 
log ( t ) log (%) remain 
Release     
Rate 
(Cumulative 
% Release/T)  
1/Cum% 
Release 
Peppas    
log 
q/100 
Hixson 
Crowell 
Model 
Modified 
Cube Root 
Equation 
0 0 0   2    0 0 
11.32 2 1.4142 1.0538 0.3010 1.9478 5.66 0.0883 -0.9461 2.2453 5.0415 
19.21 4 2 1.2835 0.6026 1.9073 4.8025 0.0520 -0.7164 2.6781 7.1727 
29.43 6 2.4494 1.4687 0.7781 1.8482 4.905 0.0339 -0.5312 3.0874 9.5322 
40.25 8 2.8284 1.6046 0.9039 1.7763 5.03125 0.0248 -0.3952 3.4270 11.7447 
58.32 12 3.4641 1.7658 1.0791 1.6199 4.86 0.0171 -0.2341 3.8779 15.0387 
99.21 24 4.8989 1.9965 1.3802 -0.1027 4.13375 0.0100 -0.0034 4.6293 21.4307 
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Table: 22 Parameters fitted in various Mathematical Models 
 
8.5 Stability Studies 
Table: 23 Accelerated Stability Study 
 
Parameters 
Storage condition 
40ºC ± 2ºC & 75% ± 5%RH 
Initial 1st month 2nd month 
Average weight (mg) 490 492 489 
Assay (%) 99.75 100.21 98.92 
 
Table: 24 In vitro Dissolution study 
 
Dissolution Time points 
 
Storage condition 
40ºC ± 2ºC & 75% ± 5%RH 
Initial 1st month 2nd month 
2nd Hour 12.56 11.96 12.01 
4th  Hour 25.12 24.97 25.08 
8th Hour 42.54 42.21 41.91 
12th Hour 68.21 66.32 68.32 
24th Hour 98.21 97.98 98.21 
Parameters  R (CvT) 
R(CvRo
ot(T)) 
Time vs 
Log© 
Log T 
vs Log 
C 
Rel Rate 
vs Cum 
Rel 
Rel Rate 
Vs 
1/cum 
Rel 
Time Vs 
Log % 
Remaini
ng 
Slope 4.1250 20.7981 0.0377 0.8981 -55.208 0.0480 -0.0201 
Correlation 0.9950 0.9630 0.9206 0.9980 -0.8398 0.8167 -0.9039 
   r2  0.9900 0.9274 0.8475 0.9960 0.7053 0.6670 0.8171 
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9. Discussions 
9.1 Preformulation Studies 
9.1.1 Raw Material Analysis 
 From the raw material analysis of Losartan potassium it is found that all 
the evaluation parameters are within the specification limits given in Table: 10. 
9.1.2 Drug-Excipient Compatibility Studies 
 Physical Observation 
 The physical examination of all mixtures of drug and excipient has been 
found that no characteristic colour change and all portions of the mixture of powder 
are visually compatible the results were given in Table: 11. 
 FT-IR Studies 
 The Infrared spectra of Losartan potassium standard drug showed sharp 
peaks at 3186.79, 2956.34, 2871.49, 1459.85, 1260.25, 996.053, 764.637 cm-1. 
These peaks were found to be prominent in the spectra of physical mixture 
containing drug polymer and other excipients were shown in Fig.8 and Fig.9. 
 Thermal Analysis 
 DSC thermograms of Losartan Potassium with Excipients depicted in the 
Fig.10 showed no changes in the endotherms when compared with the thermogram 
of the pure Losartan Potassium in the Fig. 11. This was confirmed by observing the 
sharp melting point endotherm of Losartan potassium at 70.81ºC and coated 
formulation. From the DSC thermo grams it was clear that there was no specific 
interaction between the drug and polymer used in the present formulation. 
9.1.3 Evaluation of Physical Mixture 
 The evaluation of physical mixture expresses that the values of 
compressibility index and angle of repose were found to be within the specified 
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limits given in Table: 12. From this it indicates that all the batches have good flow 
property and also suitable for compression. 
9.3  Optimization of variables  
9.3.1 Effect of Osmogent Type  
 From the Table 14, the drug release from the system may vary according 
to the type of the osmotic agent used. This is due to the different osmotic pressure 
produce by different osmotic agent. Lactose showed good and controlled release 
over sodium chloride upto 16 to 20 hour was depicted in the Fig. 12.Whereas 
sodium chloride, because of higher osmotic pressure the drug release was found to 
be completed by 12 hour. Further study has been carried out taking lactose as 
osmogent and also a diluent possessing little osmotic pressure (23) is given in 
Table: 1. Previously Mannitol had chosen as an osmotic in the push pull osmotic 
pump development65. Losartan Potassium being freely soluble drug it required less 
hydration pressure for controlled release over prolonged period of time. 
9.3.2 Effect of Osmotic Agent Concentration on Drug Release 
 The osmotic agent was taken in both the drug layer and also in the push 
layer. The formulation F2, F3 and F4 containing different concentration of Osmotic 
agent showed different drug release given in Table: 15. Fig.13 depicts the influence 
of osmotic agent concentration on drug release. From this F2 formulation containing 
200mg of osmotic agent was optimized as it had shown drug release about 97% after 24 
hours, whereas F3 showed 70% of the drug release from system after 24 hours and the 
formulation F4 was released much earlier than the desired release rate. F3 showed less 
response and the release rate is not up to the desired level. Whereas F4 shows fast release 
and the drug release could not be extended for 24 hours. 
9.3.3 Influence of Orifice Diameter on Drug Release 
 Orifice diameter is one of the critical parameters that greatly affect the 
release rate of the osmotic drug delivery. The orifice diameter must be optimized to 
control the drug delivery from the osmotic system. The orifice diameter should be 
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reasonably large to prevent bursting of the osmotic system due to the hydrostatic 
pressure produced with in the system and also at the same it should not be large 
which results in free diffusion of the drug which in turn leads to loss of control over 
the release rate. Table: 16 gives the cumulative percentage release of drug with 
corresponding orifice diameter. Different sizes of delivery orifice were made in the 
range of 250 (F7), 450 (F5), 550 (F6) and 850 µm (F2). The percentage drug 
released approximately from the corresponding formulations after 24 hours were 
72%, 98%, 96% and the formulation F2 having higher orifice diameter showed 
higher release rate and hence the maximum therapeutic concentration was attained 
in 12  hour and the release could not be extended not more 12 hours. The 
formulations F5 and F6 showed release over 24 hours but among the two 
formulations the release of drug from the Formulation F4 showed controlled release 
over the F5 formulation. The comparison of release rate corresponding to orifice 
diameter was shown in Fig. 14.  Orifice diameter had great influence on drug 
release. The formulation with 450 µm (F5) showed better response when compared 
with the other three formulations. The orifice diameter of 450 µm was used in 
further proceeding of the study. 
9.3.4 Effect of Polymer Concentration on Drug Release 
 The release of freely soluble drugs was expected to be controlled by the 
Polyethylene oxide used in the lower push layer by hydrogel formation65. Three 
concentrations of Poly Ethyleneoxide of high molecular weight were taken in the 
lower push layer 50mg, 100mg and 200mg were taken for the study. The release rate 
of the drug depends upon the concentration of the polymer present in the lower 
layer. Fifty milligram of the polyethylene oxide taken in the lower layer causes the 
drug to release faster as the polymer concentration is too low. Polyethylene oxide 
can also be used as release retardants in case of freely soluble drug. Comparing the 
release rate of the formulation with different polymer concentrations 50 (F6), 100 
(F7), and 200mg (F8). The Formulation (F7) containing 100mg Poly Ethyleneoxide 
containing formulation shows controlled release over prolonged period of time.     
Table: 17 give the effect of polymer concentration on drug release and Fig.15 
represents the comparative drug release profile of three different formulations.  The 
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formulation F6 containing 50 mg of the polymer shows release that the system had 
release about 90% of the drug within 12 hours, whereas the formulation F8 
containing 200 mg of the polymer showed slow release rate due to its release 
retardant property, releases only 70 % after 24 hours. The formulation F7 containing 
100mg polymer shows about 98% drug release in a controlled manner for 24 hours.   
9.3.5 Effect of Membrane Thickness on Drug Release 
 The water influx is related to the osmotic pressure and coating membrane. 
Therefore the water influx is inversely proportional to coating thickness and the 
directly related to the osmotic pressure developed within the osmotic system. To 
investigate the effect of coating level on the release profiles three level of coating 
thicknesses were taken for the study  10 % (F10), 12 % (F12) and 15 % (F11) 
achieved by gaining the weight. Table: 18 indicate the release profiles of osmotic 
devices formulated with different thickness. When the coating thickness increased 
up, the percentage drug release and release rate of Losartan potassium was observed. 
The increase in coating level results in the decrease of water imbibing through the 
membrane, thus the hydration of drug layer and expansion of the push layer were 
decreased resulted in decreased drug release rate. The release of drug from the 
formulation F10 was found to be completed by the 12th hour. Whereas the drug 
release from the formulation F11 was found to be approximately 76% at the end of 
24th hour. The formulation F12 was found to have optimum release of 95% 
approximately compared with all the other formulations. The comparison of release 
profile was shown in Fig.16. 
9.4 Evaluation of Compressed Tablets 
 The compressed tablet contains both the drug layer and push layer were 
evaluated for various physical parameters namely, Hardness, Friability, Thickness 
and Assay. The values obtained after evaluation was tabulated in Table: 11, the 
values indicate that the compressed tablets were having good compressibility 
property and the drug content values were found to be within the specified limits. 
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9.4.1  Influence of Agitational Intensity on Drug Release 
 The optimized formulation is investigated to determine the intensity of 
agitation on the drug release. The agitation was carried out at 50, 100 and 150 rpm. 
The result of agitatoinal intensity on drug release was shown in Fig. 17. The results 
showed that the drug release was not significantly affected by agitational intensity. 
9.4.2  Influence of pH on Drug Release 
 The optimized formulation was evaluated for drug release response 
depending upon the physiological factors. There was no significant change in the 
drug release from the system in different dissolution medium. The response was 
shown in the Fig. 18. 
9.6  Release Kinetics 
 Dissolution data of the optimized formulation was fitted to various 
mathematical models (zero order, first order and Higuchi) in order to describe the 
kinetics of drug release. Data were treated according to zero order, first order and 
Higuchi using least square method of analysis shown in Table 21 and Table 22.  
Best goodness of fit test (R2) was taken as criteria for selecting the most appropriate 
model. When the data were plotted according to the first order and Higuchi 
equations, the formulations showed a comparatively poor linearity, whereas the 
regression value for zero order equation indicated that the drug release from 
optimized formulation was independent of drug concentration. 
 
9.7 Stability Study 
 The Accelerated stability of the optimized tablet had carried out for a period 
of two months. The optimized tablets were stored in the stability chamber at the 
required conditions as per International Conference on Harmonisation (ICH) guide 
lines. The results showed that the tablets were found to be stable and showed the 
same dissolution rate as in the initial stage. The stability data were given in                
Table: 23 and Table: 24. 
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10. Summary  
Chapter I – In the introduction chapter the principle of osmosis, types of osmotic 
agents , classifications of oral osmotic pump, basic components of the oral osmotic 
pump tablets, list of patents and marketed tablets available in the markets were 
detailed. 
Chapter II – In this chapter the literature related to this work was surveyed and a 
brief discussion had been given on each literature. 
Chapter III – In the third chapter the scope work was discussed. The objective of 
the work was to develop an oral push pull osmotic pump containing an anti-
hypertensive drug and to show that the developed system would follow the zero 
order kinetics by optimizing the various formulation variables. The formulation 
variables chosen for the investigation were osmogent type, osmogent concentration, 
orifice diameter, polymer concentration and the coating thickness. 
Chapter IV -   This chapter gives an idea for the proposed plan of work that has to 
be carried out. 
Chapter V and VI - In these chapters, information about the drug and the 
excipients used in the study was given. 
Chapter VII – This chapter deals with the materials and methods used in the 
present study was given. This chapter covers the details of the experimental methods 
including evaluation of the core tablets, optimization process, and evaluation of 
physical mixture and also about the release kinetics and evaluation of the osmotic 
pump tablet were also given. 
Chapter VIII – showed the results obtained from the experimental methods were 
given in this chapter. In this chapter the figures and tables expressed the results 
graphically. 
Chapter IX – This chapter provides the complete information about the results 
obtained and the results were analysed through various tables and graphs.  
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 Pre-compressional parameters of the prepared tablets (bulk density, 
tapped density, carr’s index, and angle of repose) are in the range of given in official 
standard, indicates that the physical mixture were found to be free flowing. The 
post-compressional parameters of the tablets were found to be within the limits. The 
optimized formulation was selected for DSC and FTIR studies did not show any 
interaction between the drug, polymer and excipients. 
 In Vitro dissolution study of formulation containing Losartan Potassium 
with different concentration of the osmogent (lactose) and the polymer concentration 
(PEO) was discussed. F 12 was found to be satisfactory, where the release of the 
drug was found to be approximately 12, 28, 38, 52, 68 and 95 %. 
 The kinetics of the drug release for formulation F 12 was calculated and 
plotted. The formulation F 12 follows zero order kinetics and the drug release 
mechanism was found to be Higuchi mechanism. 
 The dissolution for the optimized formulation was carried out at 
different agitation (50 rpm, 100 rpm, and 150 rpm). It reveals that the change in the 
rate of drug release due to agitation was negligible. 
 The dissolution for the optimized formulation was carried out at 
different pH (1.2, 6.8 and pH change method). It reveals that the change in the rate 
of drug release due to pH was negligible. 
 The optimized tablets F 12 were selected for stability studies were 
carried out according to ICH guidelines at 40º C ± 2 º C for a specific period of time 
indicated that the physical parameters and drug release characteristics were not 
altered significantly showing good stability on storage. 
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11. Conclusion 
 The Push-pull osmotic pump tablet containing 100 mg of Losartan 
potassium provided controlled release up to 16 – 20 hours. In this developed system, 
lactose used as an osmogent with the drug: Osmogent ratio of 1:2. 450 µm of the 
orifice diameter showed better release profile. Similarly, the drug: polymer ratio was 
also found to be suitable as 1:1 ratio. Finally, 12 % w/w of the thickness of the 
membrane was required to control the drug release up to 24 hours. The developed 
formulation showed no deviation in the drug release and instability of the membrane 
which are characterized by different pH and agitational intensity. The push pull 
osmotic pump of Losartan potassium was found to be stable for the 2 month 
accelerated stability studies. However the invivo - invitro correlation (IVIVC) needs 
to be done after pre-clinical evaluation. 
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